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Among all the cancers, the death rate of colorectal cancer is one of the highest. 
Evidence from both murine xenograft model and human trials have shown cancer stem 
cells (CSCs) are responsible for the initiation, metastasis and recurrence of multiple 
cancers therefore targeting colorectal CSCs would be a promising chemo-preventive/ 
therapeutic strategy. Polymethoxyflavones including nobiletin (NBT) and 5-
demethylatednobiletin (5DN) are exclusively found in citrus peels and have been shown 
to have anti-cancer effects. Our previous studies in the biotransformation and tissue 
distribution of NBT and 5DN have shown that in order to fuller evaluate the biological 
impact of those two PMFs, we also need to take into consideration of their metabolites. In 
this study, we examined the effects of these NBT and 5DN as well as their metabolites on 
tumor sphere formation, apoptosis and cell cycle distribution. Plus, we also made the 
initial attempt to investigate the possible mechanism(s) for the inhibitory effects we have 
observed.  Our results showed that both NBT and its metabolites could inhibit the tumor 
sphere formation and induced apoptosis, with generally the metabolites having equivalent 
or stronger effects; On the other hand, M1 exerted the strongest inhibitory effect on 
colorectal CSCs compared to 5DN and other metabolites. Apoptosis, necroptosis as well 
as forcing CSCs to reenter the cell cycle from the quiescent states could be accounted to 
the overall inhibitory effects of NBT, 5DN and their metabolites.  
With the achievement of our study, we will be able to better evaluate the overall 
efficacy of PMFs-based (NBT and 5DN) chemopreventive strategies on colorectal cancer, 
especially against colorectal CSCs. 
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In this industrial world, colorectal cancer is among the most commonly diagnosed 
cancers. In the United States, it is the third leading cause of death among cancers in both 
men and women. Multiple barriers obstruct the successful colorectal treatment. Among 
all the challenges, tumor reoccurrence and metastasis are two major survival-influencing 
factors of colorectal cancer. For example, up to 40% of colorectal cancer patients who 
present with stage II or III colorectal cancer will recur after primary treatment [1]. Plus, 
despite the rapid advances in chemotherapeutic drugs targeting colorectal cancer, 89% 
patients with metastatic disease cannot survive [2] . This indicates that conventional 
therapies fail to provide a permanent cure. 
There is growing amount of evidence supporting that the cellular heterogeneity 
found in tumor, is one major factor that hampers the search for new therapies for cancer. 
Specifically, a small sub-population within the cancers, namely, cancer stem cells (CSCs) 
are responsible for tumor initiation, metastasis and resistance to conventional therapies 
such as chemotherapy and radiotherapy. So far, data have been accumulated that several 
solid tumors, including breast [3], brain [4] and colon [5, 6], follow the CSC model. Thus, 
with our developing understanding of the mechanism through which CSC direct the 
tumor growth, targeting CSC has become a very promising preventive/ therapeutic 
strategy that can ultimately lead to an effective colorectal cancer control. 
Compared to other types of tumor, the development of colorectal cancer usually 
requires a long time span, which provide us with a great opportunity for early detection 
and prevention [7]. Cancer Chemoprevention, by definition is the inhibition, delay and 
	  
2	  
reversal of the carcinogenesis by the administration of one or more naturally occurring 
and/or synthetic agents. Recently, the plausibility of naturally dietary compounds as 
cancer chemopreventive agents has been discussed extensively mainly for the following 
reasons [8]: 1. As most of dietary compounds are present in food that people are 
commonly consuming, they are generally easy accessible and cost-effective. 2. Compared 
to most drugs used in chemotherapy, they have low or even none toxicity, therefore there 
will be less concern about the potential side effect. 3. As has been reported by several 
clinical trials, many of the dietary compounds have already been proved to effect 
adjunctively with chemotherapy drugs. Epidemiological and dietary interventions studies 
in both animal and human models have suggested the positive role of many dietary 
components in inhibiting, reversing tumor development in different type of cancers [9]. 
So far, several of the dietary agents have also been shown to interfere with the function of 
CSCs [10]. Generally, this would be achievable by strategies such as inducing of 
differentiation, inhibiting of self-renewal signaling pathways and sensitizing CSC to go 
through death pathways such as apoptosis and cell cycle regulation [8]. For example, 
curcumin was reported to be able to impair the WNT signaling and cell-cell adhesion 
pathway in human colon cancer cell (HCT-116), which resulted in apoptosis and G2/M 
cell cycle arrest [11]. 
Polymethoxyflavones (PMFs) are a group of compounds that are almost exclusively 
found in the peels of citrus fruit [12]. So far, PMFs have been found to have wide 
spectrum of health promoting effect including anti-inflammation and anti-carcinogenesis 
[13]. Previously, as one of the major permethoxylated PMFs, nobiletin (NBT) has been 
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reported to have various biological properties such as anti-tumorgenesis, anti-
inflammation and oxidative stress [14-17].  
Among all types of PMFs, 5-demethylated PMFs are a unique subclass, with 5-
demethylated nobiletin (5DN) as the most abundantly one that could be found in orange 
peels (especially in aged orange peels) [18]. The transformation from NBT to 5DN can be 
happened under the “aging process” of orange peel (e.g. heating) or naturally by auto-
hydrolysis. Recent study have shown that 5DN exerted stronger inhibitory effects on the 
growth of the colon cancer cells compared to their permethoxylated counterparts, NBT, 
suggesting the critical role of hydroxyl group at 5-position in the function of 5-hydroxy 
PMFs [18]. Until now, there are multiple reports regarding the bioactivities of 5DN [12, 
18, 19]. 
Biotransformation plays an important role in the biological activities of orally 
ingested bioactive compounds. In fact, 3´-demethylnobileti  (N1) [20], 4´-
demethylnobileti (N2) [21], and 3´,4´-didemethynobiletin (N3) [22] were already been 
identified as major metabolites from NBT and have recently been studied for their 
biological actions. Evidence have supported that metabolites of NBT, exerted much 
stronger anti-inflammatory [23] and anti-mutagenic [24] effect compared to the parent 
compound in the in vitro setting. Plus, our unpublished data have shown that, after oral 
feeding of NBT (1000ppm) to mice, the majority of NBT was transformed into three 
major metabolites; specifically, in the mice colon mucosa, there were significant higher 
concentrations of metabolites than NBT. As a result, we need to include the metabolites 
in our study in order to fully evaluate the biological impact of NBT on colorectal CSCs. 
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On the other hand, the metabolites of 5DN have been scarcely investigated. 
Recently, our group successfully isolated and identified three novel urinary metabolites of 
5DN, namely, 5,3’-didemethylnobiletin (M1), 5,4’-didemethylnobiletin (M2), and 
5,3’,4’-tridemethylnobiletin (M3) [25]. Notably, all three metabolites have showed 
stronger inhibitory effect in human colon cancer cells then 5DN in the in vitro setting 
[25]. Moreover, according to our unpublished data, after feeding of 5DN (1000PPM) to 
mice, about half of NBT get transformed into three major metabolites (M1, M2 and M3); 
specifically, while 5DN was still the most abundant one in the mice colon mucosa, the 
three metabolites in total was more than the amount of 5DN. This again provide us the 
rationale that we need to include the metabolites in out study in order to fully evaluate the 
biological impact of 5DN on colorectal CSCs.  
 Taken all these together, out long term goal is to improve the current chemo-
preventive strategy for colorectal cancer. To achieve this goal, the overall objective of our 
research will be focused on developing novel chemopreventive -based strategies that 
target colorectal CSC using multiple PMFs. Our central hypothesis is that NBT, 5DN and 
their demethylated metabolites will exert their anti-CSC ability by regulating major CSC-
associated cellular signaling pathways. Our hypothesis has been formulated on the basis 
of our and others’ preliminary results that NBT, 5DN and their demethylated metabolites 
have already shown anti-cancer effects both in vivo and in vitro, with the metabolites 
showing much more potent effect than their parental compounds. 
We plan to test our central hypothesis, and thereby, achieve our objective of this 
project by pursing these following specific aims: 
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1. Determine the inhibitory effect of NBT and their demethylated metabolites on 
colorectal CSCs. The inhibitory effect of NBT and their metabolites will be analyzed by 
tumor-sphere formation assay. Flow cytometry analysis will be utilized to determine the 
effect of NBT and their metabolites on cell cycle distribution and apoptosis. Western blot 
on various key CSC- related markers, and oncogenic proteins will be conducted. We 
anticipate seeing that both NBT and their metabolites will have inhibitory effects on 
colorectal CSCs, with possibility metabolites having stronger effect. 
2.  Determine the inhibitory effect of 5DN and their demethylated metabolites on 
colorectal CSCs. 5DN and their metabolites will be investigated by using the same 
techniques as described in specific aim 1. We anticipate seeing that both 5DN and their 
metabolites would exert inhibitory effect on colorectal CSCs, with possibly metabolites 















2.1 Introduction to colorectal cancer  
As part of the gastrointestinal (GI) tract, one of the most regenerative systems in 
human body, colon and rectum (large intestine) are characterized by unique properties: 1. 
Large intestine is a 5-feet long muscular tube, which is covered by a sheet of crypts. 
Crypts are the basic functional unit of the intestine. 2. To maintain the proper function of 
the larger intestine, billions of specialized intestinal epithelial cells are replaced by new 
cells in a daily base. All these are regulated by the stem cells harbored in the base of the 
crypts [26]. These stem cells are able to maintain themselves through self-renewal.  
Depending on the different location along the crypt axis in colon, intestine cells can be 
further specialized after receiving signals to differentiate into a variety of cell types [27]. 
Over all, the highly regenerative and proliferative nature of the intestinal system makes it 
very vulnerable to multiple genetic mutations followed by the loss of proliferation control, 
which are thought to lead to colorectal cancer [28].  
In this industrial world, colorectal cancer is one of the most commonly diagnosed 
cancers. In the United States, it is the third leading cause of death among cancers in both 
men and women (Figure 1). According to American Cancer Society, there would be 
approximately 26100 and 23600 estimated deaths from colorectal cancer in male and 
female respectively in 2015. Unlike other cancers such as lung cancer, there is no single 
risk factor that accounts for the most cases of colorectal cancer. Instead, multiple risk 
factors (most of which are often interrelated) have been identified through 
	  
7	  
epidemiological studies, for example, family history of colorectal cancer [29], 
inflammatory disease [30], smoking [31], and excessive alcohol consumption [32].  
 
 
Figure 1.  Ten leading cancer types for the estimated deaths by sex in United States, 
2015. (Adapted from Siegel et al., 2015) [33] 
	  
Traditionally, there is higher incidence of colorectal cancer in developed countries in 
Europe, North America, and Oceania, while the incidence is much lower in developing 
countries of East Asia and Africa [34]. Findings from multiple epidemiologic and 
experimental investigations have shown that the risk of colorectal cancer is linked with 
the consumption of different foods and nutrients. For example, fiber, milk and whole 
grains have been associated with a lower risk of colorectal cancer, while the extensive 
consumption of red meat and other processed meat product are believed to result in a 
higher risk [35]. There are increasing data supporting that the efficacy of dietary 
modification and nutrient supplementation for the prevention of colorectal cancer [36]. 
The development of colorectal cancer usually begins with a growth of tissue or 
tumor as non-cancerous polyps on the inner layer of the colon or rectum. While most of 
the polyps are considered to be benign tumors (adenomas), only the certain polyps 
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(carcinoma) can be further developed into cancer. As most colorectal cancers develop 
over several years, from adenoma to carcinoma, the disease is most curable if detected at 
early stages. Multiple observational studies suggest significant reduction in the incidence 
and mortality of colorectal cancer by screening colonoscopy, which prevents cancer by 
allowing for the removal of precancerous lesions [37, 38].  
For the recent years, compared to the decreasing trend of both the incidence and 
mortality rate of colorectal cancer in developed countries, there is a rapid increase in the 
incidence and mortality of colorectal cancer in previous low-risk developing countries 
such as China. Studies have shown that this trend is related to people’s elaboration of the 
west-life style such as high-fat diet consumption. On the other hand, besides the 
underdeveloped health-care resources, people in developing countries are more reluctant 
to take the colorectal cancer screenings such as colonoscopy due to their invasive nature 
[34, 39].  
Multiple barriers obstruct the successful colorectal treatment. Among all the 
challenges, tumor reoccurrence and metastasis are two major survival-influencing factors 
of colorectal cancer. For example, up to 40% of colorectal cancer patients who present 
with stage II or III colorectal cancer will recur after primary treatment [1]. In colorectal 
cancer, despite the rapid advances in chemotherapeutic drugs, 89% patients with 
metastatic disease cannot survive [2]. This indicates that conventional therapies fail to 
provide a permanent cure. 
Overall, since the effectiveness of current treatment of colorectal cancer still remains 
a huge challenge, the long term declines in colorectal cancer incidence rates since the 
mid-1980s have been attributed to both changes in risk factors and the introduction of 
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screening [40]. However, the rapid declines in recent years would almost be attributed to 
the development of colonoscopy [41].   
 
2.2 The evolving concept: cancer stem cells (CSCs) and colorectal cancer 
2.2.1 Tumor heterogeneity  
Despite the introduction of novel therapies in cancer treatment over the years, there 
are still many patients suffering from the low survival rate of solid tumors such as 
colorectal cancer. Traditionally, most of the therapeutic approaches have been focused on 
targeting the malignant mass, of which the cell growth and survival pathways have been 
studied for decades. However, rather than archiving the anticipated clinical goal, the 
tradition treatments usually if not always have result in tumor progression and recurrence.   
In response to the therapy failure and disease progression of the conventional cancer 
therapies, more and more researchers have been focused on identifying new, innovative 
targets to guide the future drug development as well as chemopreventive strategies. 
Among all the challenging factors that have been hampering the search for new 
therapeutic target, it has been widely accepted that the intratumoral heterogeneity is the 
most important one [42]. In another word, rather than simply as a collection of 
homogeneous cells, tumor is more likely a complex organization consists of cells with 
different functions. All these cells, as a whole, influence the development of tumor, and 
ultimately impact the efficacy of certain therapy [43]. Individual cells within a tumor 
could be various in multiple aspects such as growth, metabolism and apoptosis [44].  
It was more than two decades ago that Vogelstein [45] pointed out that just like most 
eukaryotic organism begin as single cells (eukaryotic stem cells), a tumor might also 
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starts from  a single cell and then develop into a heterogeneous system. Thus, the 
understanding of tumor heterogeneity will be of great importance in the flowing two 
aspects: 1. It will provide insights to the biological base of tumor development and 
critical events such as initiation, metastasis and resistance to therapy; 2. It will be helpful 
in guiding the direction of future development of cancer-preventive/ therapeutic 
interventions. 
Firstly, the tumor cell heterogeneity at the genetic level is one major factor that 
account for the generation of cell diversity within a tumor. With the advance of whole 
genome sequencing technique [46, 47], there are increasing studies supporting that the 
variability at the DNA level, or, multiple genetic alterations that accumulated during the 
progression of cancer, can be account for the phenotypic diversity among tumor cells.   
In addition to the genetic difference that contributes to the tumor cell heterogeneity, 
epigenetic mechanisms can be another factor. Unlike changes at the DNA level, 
epigenetic modification including methylation, acylation, ubiquitination, phosphorylation 
and non-coding small RNAs (miRNAs) [48] do not result in alterations in primary DNA 
sequence while can still alter the transmission of information through cell division [49]. 
Overall, multiple data support that those epigenetic factors not only play a very important 
role in normal tissue functioning, they also contribute to the functional heterogeneity in 
cancers [50, 51]. 
Given the fact that there are both genetic and non-genetic factors that can lead to the 
cellular heterogeneity in cancer, it is of great importance to understand that whether all 
cells within a tumor have the same biological potentials that can be account for the tumor 
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sustainability, or, is there a particular sub-population of cancer cells that are responsible 
for the tumor- initiating? 
A traditional view of the cellular heterogeneity is known as the stochastic model. It 
is based on the assumption that since every single cell within a tumor are “equally 
created”; it is the random variables that decide the fate of cells. In other words, whether 
or not some cells would possess tumor-initiating ability is simply a stochastic event with 
relatively low probability [28]. In fact, the stochastic model is in contradiction to the 
hierarchies in the development of normal organs, where stem cells serve as the most 
potent cells and have the potentials to differentiate into cells of specific lineage. Plus, 
with this stochastic model, it basically denies the possibility that cells with tumor-
initiating potentials can be separated from bulk tumor.  
On the other hand, there is the hierarchical model, also known as the cancer stem 
cell (CSC) model, which is based on the prediction that bulk tumor cells are consist of 
intrinsically different subpopulations: tumorigenic and non-tumorigenic. Within the 
hierarchically system, only a small population of tumorigenic cells, or cancer stem cells 
(CSCs), are able to give rise to phenotypically and functional diverse non-tumorigenic 
cells.  
According to the hierarchical model, only CSCs have the ability of long-term self-
renewal, therefore maintaining the growth and progression of cancer [52]. On the other 
hand, differentiated non-tumorigenic cells will be consisting the bulk of tumors, though 
had almost no contribution to the cancer progression. Prospectively, the separation of 







Figure 2. Two models that demonstrate the tumor heterogeneity. A. The stochastic 
model. According to this model, every single cell within the tumor has the tumor-
initiating potential. B, The hierarchical (CSC) model.  According to this model, there is 
only a small sub-population of cells (CSCs) are responsible for initiating and maintaining 
tumor growth. 
	  
2.2.2 Defining the “Stemness”  
As has been reviewed above, there is increasing evidence supporting that rather than 
a collection of homogeneous malignant cells, tumor is more a complex systems with 
functionally diverse cell types which influence the overall tumor “fitness” [44]. 
Historically, principles from normal stem cells (NSC) have been guiding the developing 
of cancer stem cell (CSC) study. Even though CSC may not necessarily derive from the 
normal NSCs, they could still possibly share multiple signaling pathways [53]. One of the 
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key characteristics of stem cells is self-renewal. By definition, self-renewal is the 
biological process where cells can undergo either symmetric or asymmetric division to 
form daughter cells with the same biological potential, which ensure the long-term clone 
ability. Particularly, through asymmetric cell division, one CSC can give rise to two 
different daughter cells. While one of the daughter cell will maintain the long term self-
renewal properties as the mother cell, the other cell can be further specialized according 
to the different developmental stage [54]. While through symmetric cell division, each 
CSC can divide symmetrically to generate either two daughter stem cells or two 
differentiated cells [55]. (Figure 3) 
 
 
Figure 3.  Asymmetric and symmetric division of CSCs.  
 
There is increasing use of the term “stemness” to describe the functioning as well as 
the serial unique biological properties of CSCs. Generally, “stemness” has been used to 
characterize the multi-lineage differentiating potential while retaining the ability to self-
renewal [56].  
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The ultimate goal for the study of CSC, as has been pointed out by Kreso et al. is to 
get a complete view of the underlying mechanisms of the tumor heterogeneity; and how 
such how they are connected to critical challenges such as therapy resistance and tumor 
progression and relapse [44]. Recent observations in human studies of leukemia and solid 
tumor begin to support the central role of the “stemness” in the cancer study [57-60]. In a 
recent review, the authors for the first time provide us with the notion that three 
fundamental filed in biology: genetic factors, epigenetic modification (e.g. DNA 
methylation, histone modification), as well as the non-malignant cells within the 
microenvironment (niche), could be accounted for the functional heterogeneity in the 
tumor; more importantly, such factors could either simultaneously and /or independently 
impact the “stemness” of the CSC [44]. Thus, a more detailed illustration of the  
“stemness”, as well as some of its key regulators will be further reviewed in the following 
chapters.   
2.2.3 Purification of colorectal CSCs 
2.2.3.1 CSC markers: popular yet controversial  
Generally, the investigation of CSCs have been focused on the use of cancer cell 
lines, primary cancer cell lines, xenografts from murine model as well as primary human 
patient tissue sample [61]. Specifically, certain CSC surface markers have been widely 
used in various CSC models. 
During the early studies of leukemia [62, 63], researchers successfully utilized the 
tools such as fluorescence- activated cell sorting (FACS) and xenograft in 
immunocompromised mice model to separate CSCs and thereby have them subjected to 
functional assays. However it took decades of efforts for people to apply the similar 
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principles from leukemia/ hematopoietic system to solid tumor such as colorectal cancer. 
Followed by the initial study in breast cancer [3], more and more progress has been made 
in identifying cancer stem cells in several cancers such as brain [4], pancreas [64, 65], 
lung [66].  
Human colorectal CSCs were first isolated based on the cell surface CD133 in 2007 
[5, 6]. CD133 was initially known as a cell surface antigen on both hematopoietic and 
neural stem cells [67, 68]. Two independent groups utilized CD133 in different murine 
xenograft models to characterize colorectal CSCs. O’Brien et al. [5] demonstrated that 
the CD133 + cells had much stronger tumor-initiating ability compared to CD133 - cells 
utilizing non-obese diabetic/severe combined immunodeficiency (NOD/SCID) renal 
subscapular xenograft model. The similar results from the study of Ricci-Vitiani et al. 
were based on a SCID mouse subcutaneous xenograft model [6]. Both of the two studies 
have demonstrated that there is enrichment in CD133 + Cells in terms of the 
tumorigenicity, however that the CD133 + population is still far from a homogeneous 
system; rather, not every one of CD133 represent a CSC. By in vivo limiting dilution 
assay (LDA), O’Brien et al. further revealed compared to CD133- cells there is 200-fold 
enrichment in terms of the cancer stem cell activity in the CD133 + subsets [5].  
Besides CD133, other markers are also been utilized to identify the tumor-initiating 
sub-populations in colon cancer. For instance, CD44, an adhesion molecule that once 
seen as a maker for human breast cancer, got its application expanded to the identification 
of several of solid tumors such as colon [69] and pancreas [65]. Specifically, Dalerba et 
al. discovered that the combination of CD44 and epithelial cell adhesion molecule 
(EpCAM) could effectively result in an enrichment of CSCs in a NOD/ SCID 
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subcutaneous xenograft model [69]. The study was based on eight colorectal cancer 
specimens, and frequency of the tumor-initiating cells (EpCAM+/CD44+) ranged from 
0.8% to 38%. In addition, the study also focused on the efficacy of CD44 coupled with 
another marker CD166, a mesenchymal stem cell marker [70]. The previous mentioned 
publication by Weichert et al. had demonstrated the correlation between the increased 
expression of CD166 in and the poor clinical outcome in CRC [71]. According to their 
study, the colon cancer cell subpopulation that co-expressing EpCAM+/CD44+/CD166+ 
had high tumor-initiating property.  
Aldehyde dehydrogenase 1 (ALDH1) is another popular marker that has been used 
to separate CSCs from the rest of the bulk cells. As a detoxing enzyme that oxidizes 
intracellular aldehydes and therefor protects cells from alkylating stress [72, 73], ALDH1 
was found to be active in human hematopoietic stem cells (HSCs) [74]. More recent 
findings have begun to draw people’ s attentions to the use of ALDH1 to enrich human 
colorectal CSC [75, 76]. One of findings showed that as low as 100 ALDH1+ human 
colon caner cells would be able to give rise to xenografts in NOD/SCID mice (while 
ALDH- could not generate any tumor), supporting the high tumorigenicity of ALDH1+  
cells [76]. Besides, the authors also explored the combining use of ALDH1 with other 
stem cell markers such as CD44 and CD133. Interestingly, they found that only the 
combination of ALDH1 and CD133 was able to generate subpopulations with higher 
tumor-initiating capacity: while the tumor-initiating rate was 58% when only ALDH1 
was used, in comparison, the rate got increased to 89% in the xenografts from CD133+ 
ALDH1+ cells. Overall, based on their study, the authors concluded that ALDH1 was an 
ideal candidate with high specificity in identifying and isolating human colorectal CSC. 
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To date, there has already been a commercially available ALDEFLUOR assay kit, which 
can be used to detect and isolate subpopulation of cells with high ALDH expression. The 
use of such kit, as a result, has been applied in various cancer types such as lung [77], 
breast [78] and prostate [79]. 
Notably, given the multiple achievements so far in the research of the surface 
markers as a tool to detect the CSCs, ambiguous results exist. Generally, it is believed 
that the surface markers are closely related to the binding epitopes, sample size and 
analyzing methods such as western blot and flow cytometry [80]. Interestingly, some 
research even stated that the expression of CD133 is not limited to CSC in colorectal, 
rather that both CD133+ and CD133-   subsets have tumor initiating properties [81]. One 
possible reason of the opposite observation is that in vitro culture of cells before analyzed 
by flow cytometry and/or FACS, which might have potential influence on the immune- 
phenotype [81]. On the other hand, even if the cell samples are obtained from solid tumor 
specimens, it is also critical to have optimized protocols for cell dissociation, where dead 
cells and debris should be excluded before any tumorigenicity test. The small sample size 
might be another reason for the controversial results [28]. For example, for the studies of 
Haraguchi et al. [82] and Chu et al. [75], neither of them used more than 5 colon cancer 
samples. These were mostly due to the difficulty in obtaining samples from human 
patients as well as the complex procedures that would possibly be involved.  
Furthermore, it has been considered that the introduction of more than one marker 
would put another layer of complexity [28]. For example, while multiple independent 
groups studied the application of high expression of CD133/CD44 as a tool to identify 
colorectal CSC [69, 82, 83], the study of Chu et al. showed quite opposite effect, where 
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the application of CD44 alone had much more significant efficiency in isolating 
colorectal CSC, compared to the combination of CD44 and CD133 [75].  
In summary, the use of CSC surface markers should be carefully defined for each 
tissue and tumor sub-type; more importantly, even for a certain tumor type, the solely use 






CD133+ 1.8 to 24.5 [5] 
CD133+ 0.7 to 6.1 [6] 
CD133+ 0.3 to 82 [82] 
CD133+ 0.3 to 3 [84] 
EpCAM+CD44+ 0.03 to 38 [69] 
EpCAM+CD44+CD166+ 3.3 to 35.6 [69] 
CD44+ 11.5 to 58.4  [82] 
CD133+CD44+ 0.2 to 50.5 [82] 
ALDH1+ 2.5 to 4.5 [76] 
ALDH1+CD44+ 0.7 to 1.9 [76] 
ALDH1+CD133+ 0.7 to 1.1 [76] 
	  
Table 1. Isolation of colorectal CSCs by using surface markers.  
	  
	  
2.2.3.2 In vivo xenograft: the golden standard for CSC study 
Questions have been raised regarding whether using solely cell surface makers 
would be the optimal method in purifying CSCs from the bulk of cancer cells. In fact, as 
multiple studies have already found, a change in the phenotypic marker expression might 
not always indicate the unique function of CSCs [85]. Currently, the golden methods of 
detecting of CSC, as summarized by O’ Brien et al. [85] and Kreso et al. [44],  is to use 
patient tissue samples to generate xenografts in immunocompromised mice in an in vivo 
setting; thereby utilizing robust functional assays such limited dilution assay (LDA), the 
tumor-initiating capacity can be further tested.  
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Xenograft, though has been regarded as the golden standard in CSC study, is still 
facing some important challenges: for example, many researchers would doubt that the 
use of immune-compromised mice as a reliable model to address the tumorigenicity of 
human cancer. In other words, would the observation of cells with tumor-initiating 
potential in murine model be necessarily indicating the “fate” of such cells in human?   In 
response to this critical question, Shackleton [86] suggested that we need to distinguish 
the different meaning of “potential” and “fate”: while “fate” means what are or/and will 
be happening for sure, “potential” just provide the possibility that certain cells are 
capable of doing under a particular circumstances. As a result, it is understandable that 
the interpretation of the above-mentioned  “golden standard”, are mostly referring to the 
“potential” of CSCs in human.  
In reality, the function of tumorigenic cells might be vastly influenced by the 
microenvironmental and/ or immunological mechanisms (for instance, immune response 
in mice might be stronger than in patients). The importance of CSC and its 
microenvironment (niche) will be discussed in the following chapters. Therefore, high 
experimental standard should be applied in order to ensure the soundness of the results. 
Particularly, the conducing of xenograft should be optimized to overcome multiple 
barriers: for example, depending on which unique type of tumor will be investigated, the 
xenograft site should be carefully chosen and suitable for the human cancer to grow[28].  
In summary, xenografts in mice model are so far the most reliable (yet far from 




Figure 4. In vivo xenograft is the golden standard for CSC study. Theoretically, only 
CSCs can generate xenografts in the murine model; such xenografts can be further passed 
to the next generation.  
	  
2.2.3.3 In vitro sphere culture of CSCs: an effective surrogate for stem cell study  
In order to conduct functional assays to investigate the key factors in the CSC- 
related pathways, large amount of CSCs would be needed. However, given the rarity of 
CSCs in tumors (sometimes less than 1%), this is hardly achievable. Thus, a simple and 
effective method is needed for the advance for this field. In vitro cell sphere culture has 
been increasingly used for the enrichment of study of CSCs [87-90]. Specifically, non-
adherent, three-dimensional (3D) tumor spheres can be grown under serum-free condition 
after a period of time (usually 7-14 days). By quantifying the number of spheres in a 
specific sample, the sphere-forming ability (also as known as the in vitro tumorigenicity) 
of CSCs can be further estimated.  
In a mechanism study aimed to elucidate the possible regulators in the maintaining 
of the “stemness” of colorectal CSCs, O’Brien et al. tested the soundness of the in vitro 
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sphere culture assay [85]. Specifically, they compared the CSC- enriching efficacy in 
both sphere forming (serum-free) medium and colony- forming medium (with 10% FBS).  
Both of the cells from above two culture mediums were then further compared to cells 
obtained from in vivo xenograft model. According to their findings, the frequency of 
sphere forming cells is only 6- fold greater than the frequency of CSCs from the in vivo 
xenograft; while the frequency of colony- forming cells was almost 88- folder higher. 
This showed that the frequency of the sphere-forming cells was much closer to the 
“CSCs” derived in the in vivo xenograft model. The authors then determined whether the 
sphere-forming and colony-forming cells still possessed tumor-initiating capacity. By 
injecting both these group of cells into immunocompromised mice model using LDA, 
they found that the cells from sphere- forming group showed significant potency in 
generating new tumors than the colony-forming counterparts. In other words, the results 
provided solid proof that in vitro sphere culture assay can be highly trust to reflect the 
“real” CSCs frequency as would be generated by the golden standard: in vivo xenograft 
model [85]. So far, multiple independent research groups have been using in vitro tumor 
sphere formation assay as an effective surrogate in the study of CSCs, especially in 
exploring the molecular mechanisms, where large amount of samples are required [84, 
91, 92]. 
However, given the complexity of CSC, for example, the fact that CSCs are closely 
related to their microenvironment (see Chapter 2.2.4), there are also some researchers are 
questioning the soundness of the in vitro sphere culture as a valid tool for CSC study 
[93]. As a result, more progress in the CSC biology would be required for a better 
evaluation and/or even modification of our current study models; it is also possible that 
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the rising of novel study models would provide us a better insight of the “stemness”  of 
CSCs. 
   
 
Figure 5.  In vitro tumor sphere formation is an effective surrogate for CSC study. 
Theoretically, only CSCs can grow in the SFM and form 3- dimensional unattached 
spheres. Each tumorsphere are believed to have derived from one or more CSCs.  
 
2.2.4 Multiple layers of complexity 
2.2.4.1 CSCs and microenvironment (niche) 
In the study of cancer biology, the “seed and soil” hypothesis has been used to 
explain the close relationship between tumor cells (the seeds) and the microenvironment 
(the soil) of which they can survive; plus, it also helps us to understand the preferentially 
metastasis of certain cancer (e.g. colon cancer would preferably metastasize to the liver) 
[94]. According to this hypothesis, there is a “receptor-ligand” like interaction between 
the tumor and its local non-malignant cells including inflammatory cells, hematopoietic 
cells, associated stromal cells and vasculature [95]; such interaction enables the activation 
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of self-renewal pathways, which will eventually re-initiate the tumor growth in other site 
[96].  
Accumulating evidence are supporting that just like normal adult stem cells, CSCs 
also exist in an specific microenvironment: the CSC niche. Depending on the individual 
tumor type, such niche may play either an inductive or selective role in regulating the 
function of CSC [95]. So far, the brain CSCs and their perivascular niche is one of best-
characterized model. Notably CSCs in glioblastoma have been shown to secrete VEGF 
which help supporting the development of local vascular cells [97]; while on the other 
hand, endothelial cells would secrete nitric oxide which induces the Notch signaling in 
glioma cells. Such bi-directional relationship has also been supported by other studies 
[98-100]. In the study of colorectal cancer, the interaction between CSCs and their niche 
is also supported by the fact that chronic inflammation which favors the cancer 
development [101], is closely related to the CSC sub-population [102]. A recent study 
has shown that the HGF-mediated activation of the Wnt signaling pathway from the 
colorectal CSC niche play a crucial role in defining the CSC state and thus are 
responsible for the induction of certain CSC phenotype [103]. In other words, this study 
suggested that the microenvironment could actually govern the tumor cell “stemness”. It 
has been proposed that targeting of myofibroblasts or the HGF/c-MET pathway would be 
able to interfere with the maintaining of the CSCs and thus prevent the possible induction 
of CSCs from the non-CSCs population [95].  
Understanding the role of CSC niche will be beneficial in at least following two 
aspects: 1. It will help us to evaluate of the current study model. As has been pointed out 
by Kreso et al. [28], the xenograft, even though regarded as the golden standard of CSC 
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study is still facing quite some limitations (see Chapter 2.2.3). Basically, xenograft is 
simply growing human cells in mice (the alien environment), where the 
microenvironment could be possibly different from that in human setting. Different 
microenvironment may have completely different impact on CSC behavior. Besides the 
across-species challenges, studies have also shown that even with one specie, the 
injection sites should be carefully selected since they may play very crucial role in 
influencing the frequency of CSCs. For instance, the study by Stewart et al., showed that 
compared to the ovarian bursa, there is much higher tumor-initiating frequency in the 
mammary fat pad [104].  
Furthermore, the cross talk between the CSCs and the microenvironment, not only 
has imposed another layer of complexity of the CSC- study, more importantly, findings 
support the notion that selectively or adjunctively targeting the CSC microenvironment 
may be used as an alternative for the CSC-targeting therapy [95].  
2.2.4.2 Heterogeneous within the CSC pool: Tracking single CSC down 
As has been extensively reviewed in chapter 2.2.1, the intratumoral heterogeneity is 
one of the major factors hampering the current search of new effective therapeutic target 
against cancer. Still, question arises regarding whether (functional) heterogeneity also 
exists within the pool of CSCs. If this is true, it will definitely put another layer of 
complexity to the study of cancer stem cells.  
Generally, current CSC-studying models such as surface marker expression and 
xenografting assay are unable to answer the question above; in other words, “pure” CSCs 
still cannot be isolated and studied individually. With the advancement of technologies 
such as gene sequencing, the tracking of CSCs at the single cell level is achievable and 
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has been utilized in many studies. Tracking CSC down at the single cell level has been 
believed to further reveal the nature of the potential heterogeneity based on the 
knowledge from genetic fingerprint of each tumor-initiating cells.  
As some of the recent publication have suggested, the overall effect of certain 
treatment, would rather mask the cellular variation among those CSCs seemly to be 
homogeneous [44]. A study of the Leukemic stem cells (LSCs) in acute lymphoblastic 
leukemia showed that such LSCs not only were genetically variable, but also 
demonstrates different degree of “stemness” (self-renewal and leukemogenicity)[105].  
It is until recently that progress has also been made in the study of solid tumors. By 
the combining use of both lentiviral marking and xenografting techniques in NOD/ SCID 
mice, Kreso et al. showed that rather than being a homogeneous system, the CSC 
subpopulation within the colorectal cancer is consist of tumor-initiating cells with diverse 
functionality; moreover, a gradient in proliferation in proliferation and self-renewal 
kinetics in the colorectal cancer-initiating cell pool was also observed [28, 106]. 
Interestingly, the authors also found in their study that, as some of the cells within the 
CSC pool retained the extensive self-renewal ability for as long as a year, there are still 
some cells preserve their self-renewal potential for a very short period [28, 106]. This 
pattern is similar to those have been observed in normal stem cell system or leukemic 
stem cells [105, 107]. 
In summary, multiple studies have already shown that extensive cellular variability 
also exists within the CSC population, which was thought to be a uniform system. So far 
it is not clear whether this heterogeneity would have any implication on the therapeutic 
outcome of the current anti-CSC strategies. Evidence are still vastly lacked regarding 
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whether all the cells within the CSC pool will be responded equally to certain therapy 
aimed to targeting one or more molecular site [44]. As a result, it is of great importance 
for us to take into consideration that the CSC subpopulation is an actually dynamic 
heterogonous system and therefore the effects of certain anti-CSC strategy should be 
carefully interpreted.  
	  
2.3 Targeting colorectal CSCs 
2.3.1 CSC and the clinical relevance   
With the rapid advance of modern technology, researchers have had more 
“weapons” than ever before to fight against cancer. However, in spite of the consistent 
efforts in developing novel therapies for the treatment of cancer, we generally fail to 
improve the patient overall survival [108, 109]. Aggressive tumor growth, which is often 
linked with metastasis of malignant tumor to remote sites, contributes mostly to the poor 
prognosis for overall survival [110].  There is growing amount of evidence supporting 
that the cellular heterogeneity found in tumor, is one major factor that hampers the search 
for new therapies for cancer. In other words, the “stemness” properties of CSCs enable 
them to be highly relevant to the clinical outcome.  
So far, it is still controversial regarding the soundness of using CSC surface makers 
as predictors of clinical outcome of cancers. For instance, a meta-analysis of totally 15 
studies shown that high expression of CD133 was indeed an independent prognostic 
marker for over-all survival and disease free survivals; in other words, CD133 over-
expression was not significantly related with multiple clinicopathological parameters 
[111]. However, according to another study, it has been shown that CD133 expression is 
correlated with poor prognosis in colorectal cancer [112].  Similarly, it was found that 
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leukemia-initiating cell fractions defined by functional assays from human patients, was 
highly related to the clinical outcome; however, such correlation was not observed when 
using phenotypic surface markers to define the L-IC fractions [58]. This study showed 
the importance of functional assays in the CSC research and also supported the notion 
that using of surface marker as “clinical predictor” is sometimes insufficient or even 
unreliable.  
Plus, recent gene expression profiling study was able to provide more insights into 
the prognostic significance of CSCs. In a colorectal cancer study, the receptor tyrosine 
kinase EphB2, a Wnt target gene, was used to characterize CSCs from colorectal tumors 
in human patients [60]. Interestingly, the study showed that compared to other current 
clinical predictors, the high expression of EphB2 is much more efficient in predicting 
tumor relapse in patients after two years of treatment [60]. According to similar findings 
reported by Pece et al., the purified stem cells sub-set in the mammary tumor is one of 
the major factors distinguishing breast cancers of different grades and molecular types 
from each other; notably, by combining the observations in the expression of surface 
marker as well the functional assays such as xenograft, they concluded that poorly 
differentiated tumor sub-types contained higher portion of CSCs population compared to 
their extensively differentiated counter-part [113].  
As a matter of fact, there is so far still very limited number of publications regarding 
clinical trials incorporated with the study of CSCs. In a breast cancer study, Li et al. 
compared the potential change of the CSC subpopulation after traditional chemotherapy 
alone and those with the addition treatment of lapitinib [114]. According to their results, 
only the additional treatment of lapitinib resulted in the change of phenotypic marker 
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expression, more importantly, a functional change was also observed through the 
xenograft-forming assay. In spite of the fact there are still no clinical studies on colorectal 
CSC have been published yet, efforts have been already made in elucidating the clinical 
relevance between CSC and colorectal cancer. One of the pioneering studies by Kreso et 
al. showed that human colorectal CSC function is highly dependent on BMI-1 [106]. The 
down-regulation of BMI-1 resulted in a significantly decrease of the self-renewal 
properties in the colorectal CSC, which in turn lead to the effective control of the in vivo 
tumor growth [106]. 
In summary, despite the fact that there is still yet an agreement among researchers 
regarding whether all the tumor types would be following the CSC model; however, the 
interests on the CSC and their clinical relevance have been accumulated in rapidly in 
recent years. Particular, data are supporting rather than the changes phenotype changes, it 
is the functional signature, namely, the “stemness” of CSCs that is closely linked to the 
clinical outcomes such as prognosis and therapy failure [60, 115]. Such “stemness” 
nature enables CSCs to make a balance between proliferation, survival and differentiation 
and thereby render them the resistance against conventional radiotherapies and 
chemotherapies. One vivid analogy by Winquist et al. stated that if the all the cells and 
signaling events can be seen as an endless train consists of a string of boxcars; targeting 
cancer stem cells is just like removing the locomotive engine. Even though the extricating 
of the engine might not impact the size of train immediately, however it would stop the 
train from further activities such as metastasis and relapse [116]. In order to develop more 
effective CSC- targeting strategies, it is very importance to gain a better understanding of 
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the possible molecular mechanisms through which CSCs exert their resistance against 
conventional therapies. 
 
Figure 6.	  The clinical relevance of CSC. Conventional therapies may be efficient in 
eliminating the “bulk ” of cancer cells (de-bulking), however, with CSCs been left behind, 
tumor relapse and metastasis will be followed; Only by targeting CSCs, tumor 
elimination can be achieved.  
	  
2.3.2 CSC and its therapeutic resistance: possible mechanisms 
To date, there have been increasing number of studies suggesting that the CSC 
subpopulation demonstrates a stronger capability in resisting both the radiation and 
chemotherapies than the non-CSC counterpart in many solid tumor types[117, 118]. Plus, 
Todaro et al. observed in their study that CSCs and non-CSCs responded differently 
when treated with traditional chemotherapeutic agents such as 5- fluorouracil and 
Oxaliplatin. Multiple mechanisms could be account for the resistance of CSCs.   
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Firstly, It has generally been accepted that many cancer are resistant to radioactive 
treatment due to the existence of CSCs [119-121]. In a study of glioblastomas, Bao et al. 
showed the radioactive resistance of CD133+ CSCs could be explained by the up-
regulation of the DNA damage response (DDR). The authors further reported that such 
resistance could be vastly weakened by inhibition of DNA damage checkpoints Chk1 and 
Chk2. Such Chk1/2 response would therefore have great targeting potential in the 
development of the CSC-sensitizing agents in the response of the radiation therapy [109, 
117]. 
Conventional anti-cancer therapies (chemotherapies/radiotherapies), may be 
effective at de-bulking the tumor, where they target proliferating cells and require active 
cycling for induction of apoptosis [122]; while for CSCs, as cells with the quiescence or 
slow cycling nature, would survive the conventional therapies and have the potentials to 
re-enter the cell cycle and re-establish a new tumor in situ (tumor relapse) or at a distant 
site (metastasis) [122]. Even though the detailed information on the specific signaling 
pathways through which the slow cycling CSCs exert the death evading behavior is still 
limited, some of the key regulators of the quiescence of CSCs have been proposed by 
some groups. For example, in the colorectal cancer cell line HCT116, p21 null cells were 
shown to have 10-fold lower tumor initiating ability compared to the normal p21 
expressing cells [123]. Specifically, the authors found that the p21 null cells were unable 
to form tumor spheres in vitro. The p21- dependence sphere forming was further 
demonstrated to be related to the lack of expression of E-cadherin and suppression of 
apoptotic signals. The author further proposed that besides the tradition role of p21 in the 
cell cycle regulation, it also could be obtaining the “pro-tumorigenic” capacity [123]. As 
	  
31	  
a result, any agents targeting p21 or its down-stream genes, would possibly be able to 
break the quiescent status of CSC and thus force them to re-enter cell cycle or undergo 
apoptosis; once becoming “cycling ”, CSCs would be much more likely to be eliminated 
[122]. In a word, the quiescent (slow-cycling) nature of the CSC subpopulation, would at 
least partially account for their resistance against the conventional therapies. 
For both normal stem cells and CSCs, the ATP-binding cassette (ABC) transporters 
serve as drug efflux pumps, which enable cells survive a wide range of xenobiotics [124]. 
As a result, the ABC transporters have also been known as “guardians of CSCs” [125]. 
High levels of ABC transporters would mostly, if not always, be a sign of poor prognosis. 
For example, some researchers have observed reduce in the 4- year survival rate of 
patients expressing high level of ABCC11 [126]. Other ABC transporters including 
multidrug resistance transporter (MDR1) and breast cancer resistance protein (BCRP) 
also have been proved to be CSC related. Specifically, MDR1 has been suggested to 
remove vinblastine [127] and paclitaxel [128], while BCRP helps avoid the accumulation 
of imatinib mesylate [129], and methotrexate [130] . So far, evidence have already 
supported that the over-expression of BCRP could be directly related in multiple human 
tumor types, such as liver cancer [131] and breast cancer [132]. 
As mentioned above, targeting DNA damage response (DDR), ABC-transporters, 
and multiple key regulators in the quiescence nature of CSC could be promising 
strategies to overcome the drug resistance in CSC. Still, there are many other possible 
mechanisms can be account for the radioactive/ chemo resistance of CSC. For example, 
ALDH, (see chapter 2.2.3.1) as an important CSC surface marker, has also been related 
to the resistance of CSCs: high ALDH1 activity has also been accounted for the 
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resistance of chemotherapy for multiple tumor types. In a study of the colorectal cancer, 
Dylla et al. found that the tumor-initiating ability was higher in the ESA+CD44+ALDH1+ 
than in the ESA-CD44-ALDH1- cells. Interestingly, the inhibition of the ALDH1 activity 
by either short –hairpin RNA interference (RNAi) or the specific ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) was unable to directly induce significant decrease in 
the xenograft growth; however, such inhibition of ALDH did result in the increased 
sensitization of cells to the treatment of cyclophosphamide, and led to a significant 
decrease in the xenograft growth [73]. Similar results were also observed in other studies: 
for example, sulforaphane (a bioactive compound found in cruciferous vegetables such as 
broccoli) has been shown to be able to reduce the ALDH activity thus render the 
CD44+ALDH+ cells sensitive to chemotherapy /radiotherapy [133]. In a study of 
colorectal cancer, Todaro et al. found that the colorectal CSCs were chemosensitized by 
an interleukin-4 blocking antibody. This suggested that autocrine stimulation of IL-4 
receptors on CSCs may contribute to their chemo resistance and thereby would render a 
promising alternative strategy to sensitize CSCs to cytotoxic chemotherapies [84]. 
With the accumulation of our understanding of the molecular mediators that regulate 
the therapeutic resistance in CSCs, it would be rational to prioritize the targeting of such 
mediators. However, it should also be taken into account the complexity of the CSC 
system: for example, some study indicated that the mechanism of chemotherapy 
resistance is possibly drug-specific [73]; moreover, it is still not clear that whether certain 
mechanism of resistance could be applied in different tumor type models. To better 
decipher such mechanism, deeper insights of the CSC biology will be required.  
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With the understanding of the stemness as well as its implication on the clinical 
outcome such as the failure of the conventional therapies, more and more focus have 
been focused on the development of novel anti-cancer therapies targeting CSCs. So far, 
the direct targeting of CSC can be achieved by inhibiting self-renewal pathways or by 
interventions on the cell death pathways such as apoptosis and cycle regulation [134]. 
 
2.3.3 Targeting self-renewal signaling pathways in CSCs 
The application of CSC surface markers, as many researchers believes, can only take 
us so far in terms of the studying of the very nature of CSC [135]. As has been discussed 
in detail above, the fundamental biological property of CSC is self-renewal. Upon cell 
division, self-renewal enables a stem cell to generate one (asymmetric division) or two 
(symmetric division) daughter cell, which maintains the long-term tumor growth. The 
capacity of self-renewal is actually the only property that distinguishes CSCs from the 
rest of tumor cells. Therefore, targeting the self-renewal has been proposed as a 
promising therapeutic goal [106, 136-138]. With the advances in understanding signaling 
pathways in normal intestinal stem cell in recent years, the knowledge of how such 
pathways are regulated or deregulated in colorectal CSC is till vastly unknown. Several 
transgenic studies in murine model have already proved the close relationship between 
activation of the self-renewal pathways and the maintenance of stemness [139, 140]. So 
far, studies on the human CSC xenografts models are still vastly limited.   
Among multiple deregulated self-renewal pathways are functioning to maintain the 
CSC properties, the WNT pathway, the Notch pathway, and the Hedgehog pathway are 
generally considered as key players [141]. 
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The aberrant WNT/ β-catenin pathway, first studied by Jamieson et al. was shown to 
be the key driving force of human blast crisis leukemia stem cell (LSC) [142]. Similar 
results were obtained later in solid tumor study. For example, Vermeulen et al. identified 
WNT activity to be one of the defining features of colorectal CSC. In their study [103], 
only cells with highest level of WNT pathway activation possess CSC properties. In 
addition, by genetic knockdown of protein phosphatase and tensin homolog (PTEN), 
Korkaya et al. found the increase in WNT/ β-catenin activity, which indicated that self-
renewal of breast cancer stem cell was mediated by β-catenin signaling [143]. 90% of 
colorectal tumors have a mutation in key regulator (such as APC) of the WNT/ β-catenin 
pathway, which result in a enhancement transcription of WNT target gene [144]. A recent 
finding found that a KRAS mutation could upregulated the WNT/ β-catenin pathway in 
the genetic background of APC loss, which generates cells with CSC phenotype and 
elevated metastatic potential [145].  
Notch pathway is another important player in colorectal CSC growth and 
differentiation [146]. Evidence have supported that Notch Pathway is required for normal 
ISCs homeostasis in mouse. Recent study has shown that inhibition of one of the 
important components of Notch signaling pathway, Delta-like 4 ligand (DLL4), resulted 
in the growth inhibition of human colon cancer xenografts [147]. Besides, Sikandar et al. 
also found that the elevated level of Notch signaling in colorectal CSC, followed by the 
prevention of apoptosis and maintenance of an undifferentiated state [148]. The essential 
roles of Notch pathway activation have also been observed in CSCs from multiple solid 
tumor types, including breast [147, 149] and glioblastoma [150]. 
	  
35	  
Hedgehog signaling pathway is a known regulator in organ development. It was 
firstly reported that activated Hedgehog signaling pathway could be observed in 
pancreatic CSC [65]. Evidence that support its role in the regulating the self-renewal 
capacity have been accumulated in pancreatic, glioma and leukemic, colon and other 
solid tumor CSC models [151-154].  
The proper function of the self-renewal also depends on one polycomb group protein 
Bmi-1. Bmi-1 is one of the first regulators, which are closely associated with self-renewal 
and involved in the maintenance of stem cell in multiple tissues [139, 155, 156]. 
Evidence have been accumulated supporting that Bmi-1 is highly expressed in head and 
neck CSCs [157]; genetic knockdown of Bmi-1 has been resulted in the impairment of 
self-renewal property in both breast [158] and brain [159] xenograft models. As has 
mentioned above in Chapter 2.3.1, a most recent study by Kreso et al. showed that the 
down regulation of Bmi-1 with a small molecule inhibitor had led to the inhibition of the 
self-renewal capacity in colorectal cancer stem cells, suggesting Bmi-1 as a therapeutic 
target in the control of colorectal cancer [106]. 
Self-renewal 
Pathways 
























Bmi-1 Bmi-1 Unknown [106] 




2.3.4 Targeting cell death pathways in CSC: apoptosis and necroptosis  
2.3.4.1 Apoptosis and CSC-regulation  
With several research have been focused on the regulation of self-renewal, 
proliferation and differentiation of CSCs, studies of cell death pathways including 
apoptosis are still quite limited [168].  
Apoptosis, by definition, is the active, strictly regulated programmed cell death, 
which plays an important “protective” role in the function of normal cells. Apoptosis 
evasion is one of the hall-markers of cancer [42]. Generally, two major pathways trigger 
apoptosis: the extrinsic and intrinsic pathways. The extrinsic pathway is active by the 
binding of extracellular pro-apoptotic ligands to cell surface receptors (death receptor) 
such as CD95, nerve growth factor receptor (NGFR), and TNF-related apoptosis inducing 
ligand (TRAIL) receptors [169]. The binding of such death receptors, are then followed 
by the recruitment of the adaptor molecule Fas-associated Death Domain (FADD) and 
caspase-8 to form the death inducing signaling complex (DISC). The caspase 8 get 
activated and initiates apoptosis through cleavage casepase-3 [170]. 
The intrinsic pathway is also known as mitochondrial pathway. It is initiated by a 
serial of stresses which generate damages in both cellular and DNA level, such stresses 
including anticancer drugs, growth factor withdrawal and hypoxia [168]. The stimuli then 
lead to a mitochondrial permeabilization and the activation of mitochondrial pathway. 
Thus, the permeability of mitochondrial membrane is a key factor in the apoptosis 
cascades and mediated by B-cell leukemia/ lymphoma 2 (Bcl-2) family proteins [171]. 
With the change of the permeability of mitochondrial membrane, apoptogenic factors 
including cytochrome c, apoptosis inducing factor (AIF), second mitochondria-derived 
	  
37	  
activator of caspase (Smac), get released from inter-membrane space into cytosol [172]. 
These are then followed by formation of the cytochrome c / Apaf-1/casepase-9 complex 
which will trigger the activation of caspase-3, leading to apoptosis eventually [173]. 
Smac promotes caspase activation by neutralizing inhibitors of apoptosis protein (IAP), 
which stands for the last protective measure against both extrinsic and intrinsic apoptosis.  
In cancer, multiple key steps with the intrinsic and extrinsic pathways are 
extensively deregulated. Recently, evidence starts to accumulate supporting the apoptosis 
pathways are also deregulated in CSCs. For example, the death receptor (DR) 4 
mediating the extrinsic pathway has a high expression in chemotherapy resistant colon 
cancer side population (SP) [174]. Since that many tumors have p53 inactivating 
mutations, stimulating of DRs has potential application as therapeutic target. The FLICE-
like inhibitory proteins (cFLIPs) are a group of negative modulator of DR induced 
apoptosis [175]. Recently, it has been reported that cFLIPs are upregulated in CD133+   
sub-population of glioblastoma [176] and breast cancer [177].  
The Bcl-2 family of proteins consists of both anti-apoptotic proteins (Bcl-2, Bcl-XL, 
Mcl-1) and pro-apoptotic proteins (Bax, Bik, Noxa and Puma) [178]. Notably, it is the 
imbalance in the ratio of anti- to pro-apoptotic molecule rather than the expression of any 
expression of particular molecule that result in cell survival and the sensitivity to 
apoptotic stimuli [178]. There is emerging evidence supporting that the resistance of stem 
cell to apoptosis is partly through the regulation of Bcl-2, while non-tumorigenic cells in 
tumors are more susceptible to the induction of apoptosis or chemotherapy [179-181]. 
For instance, it was reported that CD133+ gliomas CSCs express a high level of anti-
apoptotic proteins Bcl-2 and Bcl-XL [176]. Plus, the high expression of Mcl-1 is closely 
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related to the resistance of glioma CSCs to the small molecular inhibitor of Bcl-2, ABT-
737 [182]. Additional studies have indicted that downregulation of Bcl-2 or upregulation 
of Bax induces apoptosis of CSCs [183, 184]. All these data above support the important 
role of mitochondrial apoptosis pathway in maintaining CSC population thus become a 
promising target for preventive/ therapeutic interventions [168, 172]. 
Survivin, a member of the inhibitor of apoptosis (IAP) family, have been shown to 
regulate cell proliferation, apoptosis and pluripotency [185, 186]. Other publications have 
also been focused on other upregulated IAP proteins including XIAP, Livin in human 
CSCs [176, 187]. 
2.3.4.2 Necroptosis and CSC-regulation  
As has been discussed above, apoptosis has been demonstrated as a conserved 
pathway that regulates programed cell death. However, evidence has been accumulated 
supporting that apoptosis is not the only mechanisms that could control the cell death. 
Specifically, necroptosis, also known as the programmed necrosis, has gained more 
attention in recent years. Similarly as necrosis, necroptosis has been characterized by the 
loss of membrane integrity, rapid cell swelling and eventually lead to cell lysis; however, 
besides the necrosis-like morphology changes, necroptosis has been believed to maintains 
part of the apoptotic features as apoptosis [188, 189]. Compared to apoptosis, necroptosis 
is mostly independent of the caspase activity. Even that the understanding of the 
biochemical events mediating necroptosis is still very limited, some recent studies 
showed that necroptosis and apoptosis share some of the upstream cell signaling 
pathways. Notably, necroptosis might be activated by tumor necrosis factor α (TNFα), 
Fas ligand (FasL) and TRAIL, which are also ligands that initiate apoptosis [190]. Such 
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observation provided the notion that there might be a complex cross-talk between the 
apoptosis and necroptosis pathways. Interestingly, caspase 8 seems to be playing an 
opposite role in such cross-talk: TNF activate apoptosis by triggering a series of 
molecular events which eventually lead to the activation of caspase 8; while in 
necroptotic pathway, the function of caspase 8 is disrupted or even inhibited [191]. By far, 
some members of the receptor interacting protein (RIP) family, especially RIP-1 and 
RIP-3, have been suggested as the key molecular regulators of necroptosis [192, 193].  
Recent studies supported that necroptosis is closely related to multiple diseases 
including inflammatory bowel diseases [194, 195]. Thus, targeting necroptosis-related 
pathways might as well of important therapeutic value [196]. In light of the significant of 
necroptosis in the cancer development and control, the role of some anti-cancer drugs has 
been “rediscovered”: for example, curcumin, a well-known pro-apoptotic compound 
[197],  has been found be involved in a complex signaling network, where it might 
regulate both apoptotic and necroptotic cell death. Particularly, the treatment of curcumin 
has been shown to induce ERK or p38/ c-jun N-terminal kinase (JNK) phosphorylation at 
early time points; such induction of JNK phosphorylation would then trigger the 
formation of Reactive oxygen species (ROS), which activate necroptotic cell death in 
prostate cancer cells [198].  
So far there is no direct studies on the clinical relevance of necroptosis and the CSC-
targeting therapeutic/ preventive strategies. However, evidence has shown that certain 
necroptotic regulators also play important roles in the CSC biology. For example, a 
recent research has shown that TNFα enhances cancer stem cell-like phenotype via 
Notch-Hes1 activation in oral squamous cell carcinoma cells; particularly, data showed 
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that TNFα was closely related to the increase in tumor sphere-forming ability, stem cell-
associated genes expression, chemo/radio resistance, as well as tumorigenicity. On the 
other hand, TNFα also plays a central role in the necroptotic regulation [199].  
 In summary, apoptosis might not be the only cellular mechanism that would 
regulate cell deaths. Necroptosis, as well, has been suggested as an alternative cell death 
pathway especially when apoptosis fails because of the ATP failure (apoptosis is the most 
energy-consuming process since that it requires the activation of multiple caspases and 
the formation of apoptosome) [200-202]. The cross talk between the multiple death 
pathways, therefore need to be further understood in the development of CSC-targeting 
strategies.  
2.3.5 Targeting the cell cycle compartment in CSC 
In mammalian cells, multiple surveillance checkpoints monitors the cell cycle, 
which determines whether cells will continue proliferation or stop diving at certain stages. 
In cancers including colorectal cancer, genes regulate cell cycle progression are often 
mutated. Various regulators such as cyclins, cyclin-dependent kinases (e.g. CDK-4, 
CDK-2) and cyclin-dependent kinase inhibitors (CKIs, including p16, p21, and p27) are 
playing pivotal roles in controlling cell proliferation. Evidence also supported that 
disruption of cell cycle inhibition may also contribute to the very nature of CSCs, 
especially in breaking the balance between the self-renewal and differentiation, which 
lead to the deregulated self-renewal of CSCs [203].  
The DNA damage response (DDR) in response to the chemo- and radiation therapy, is a 
known mechanism that activates the tumor suppressor p53-induced cell cycle arrest, 
apoptosis and DNA repair [204] (see Chapter 2.3.2). Moreover, there is more and more 
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evidence supporting that cellular senescence, by assisting DNA repair machinery, 
promotes tumor progress. A good example will be that Bao et al. [117] found that the 
radio-resistance in gliomas has been associated with the activation of DNA repair in the 
CD133+ population in both human xenografts and primary patient sample. Notably, the 
activation of DNA repair can be revered through inhibiting the DNA damage checkpoint 
kinases, Chk1an Chk2. Interestingly, a recent study in mesenchymal stem cell (MSC) 
have shown the tumor-promoting role of p21 waf1/cip1 [205]. Particularly, the lack of p21 
waf1/cip1 in the background of p53 wild type led to accelerated apoptosis and inhibit tumor 
formation, while its p21 waf1/cip1 positive counterpart would result in cell senescence. Plus, 
the author also discovered the important connection between the loss of p53 and the lack 
of senescence, which is followed by increased tumor growth rate. Another study further 
demonstrated the role of p21 waf1/cip1 in maintaining self-renewal in human leukemia stem 
cell. According to the study, the DNA damage induced by oncogene activated p21 waf1/cip1 
dependent cell cycle arrest [206]. In a study on colorectal CSCs, O’Brien et al. have 
identified multiple inhibitor of DNA binding proteins (IDs), mainly ID1 and ID3, play a 
critical role in the maintenance of CSC population. Specifically, they have found that 
ID1/ID knockdown impaired the tumor-initiating capacity of colorectal CSCs and also 
increased their sensitivity to the treatment of a commonly used chemotherapeutic agent, 
Oxaliplatin. They further discovered that p21 waf1/cip1 might function to maintain ID1/ID3-
dependent tumor-initiating potential [85]. The dependence of p21 waf1/cip1 was also 
observed in colorectal cancer cell line HCT116 under sphere-forming conditions [123]: 
p21 null cells were not able to form spheres, ceased proliferation, and eventually died. 
The authors also found that such p21- dependence was related with lack of E-cadherin 
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expression and suppression of apoptosis signals, which suggested that p21 might play a 
complex role in tumor cells. It has been proposed that some small molecules targeting 
p21 or its downstream targets would be promising to force quiescent CSCs to reenter cell 
cycle or undergo apoptosis. Since that cycling CSCs would be much more susceptible to 
multiple stresses such as chemotherapy [122].  
2.3.6 Targeting other CSC related pathways  
A miRNA are small non-coding RNA, which can bind and inhibit the translation of 
targeted mRNAs [207]. They are generally considered as tumor- suppressors since they 
often regulate genes which involved in cancer cell differentiation, proliferation and anti-
drug resistance [207].  Recently, mir-34 has been reported as suppressor gene in prostate 
tumor-initiating cells[208]. Similarly, mir-21 was overexpressed in glioblastoma cells; 
while in breast cancer, it functions as anti- apoptotic factor. The use of miRNA-based 
tool to target CSCs bears promising therapeutic value [209].  
The P13K/AKT/ mTOR signaling pathway has been proved to be closely involved 
in CSC biology, especially in cell cycle progression and tumor survival [210]. Inhibition 
of Akt blocks the growth of Brain CSCs [211]. While for tumor-initiating cells in chronic 
myeloid leukemia, TGF-beta-FOXO signaling pathway is responsible for the maintaining 
of tumorigenic potential [212]. Targeting the P13K/AKT/mTOR pathway could be 
another effective strategy in therapeutically sensitizing CSCs as well as decreasing their 
frequencies in various tumor types [124]. 
The signal transducer activator of transcription (STAT) and NF-κB Pathways can be 
activated by several different cytokines and thus have been seen as potential target for 
cancer treatment [213, 214]. The study of Lin et al. showed that compared to the bulk of 
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cancer cells and ALDH-/ CD133- , ALDH+/ CD133+ cells in colon cancer expressed 
higher level of STAT3 phosphorylation. They further discovered that by treating with 
GO-Y030, an analogue of curcumin, the STAT3 phosphorylation was inhibited and thus 
resulted in reduced tumor sphere formation capacity of ALDH+/CD133+ cells [215]. The 
transcription factor NF-κB has been linked to various ontogenesis, including the 
inhibition of apoptosis by inducing the expression of survival factors [216, 217]. One of 
the examples of targeting the NF-κB pathway is that the use of Eriocalyxin B led to 
apoptosis in human ovarian CSC [218].   
In addition, pluripotency transcription factors such as OCT4, SOX2 and NANOG 
have gained quite a lot attention because of their possible impaction on the acquisition of 
stem like state [219]. Plus, evidence has shown that they are also valuable markers of 
tumorgenesis and will function as molecular regulators that determine the fate of CSC 
during cancer development [220]. For example, OCT4 has been regarded as a new 
potential molecular marker in prostate tumors [221]. The overexpression of NANOG, on 
the other hand, can be used as a predictor of tumor progression and poor prognosis in 
colorectal cancer [222]. OCT4 and SOX2 are related to distant recurrence after chemo- 
and radio- therapy in rectal cancer [223]. 
Collectively, increasing efforts have been made in the development of pre-clinical 
/clinical interference based on the hypothesis that disrupted cell death pathways in CSCs 
could be account for the failure of existing therapies for cancers. More and more 
evidence begin to support that the targeting death pathways and the deregulated cell cycle 
progression (quiescence) in CSCs is of great importance in the search of novel 
preventive/ therapeutic solutions [224].  
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Type of CSC Target Potential natural inhibitors Reference 
AML CD44 Unknown [225] 
Brain MAPK Bcl-2, Akt, XIAP 













































Table 3. Current studies on targeting the non-self-renewal pathways of CSCs in different 
tumor types.  
	  
 
2.4 Chemopreventive and CSC 
2.4.1 Introduction to cancer chemoprevention  
With the identification of cancer risk factors such as family history, obesity and 
excessive alcohol consumption and tobacco, researchers are putting more effort in 
developing preventive strategies to control the cancerogenesis [237]. Cancer 
chemoprevention, by definition, is the inhibition, delay and reversal of the carcinogenesis 
by the administration of one or more naturally occurring and/or synthetic agents. 
Historically, in despite of the huge investment of pharmaceutical companies to develop 
potent cancer preventive agents, there are so far only 10 of them have been proved by 
FDA [237]. As one of the most promising group of chemopreventive drug, non-steroidal 
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anti-inflammatory drugs (NSAIDs), have shown consistently protective effect on cancers 
especially colorectal cancer; yet the wide use of them are still limited due to the side 
effects such as a increased risk of bleeding [238]. Recently, the plausibility of naturally 
dietary compounds as cancer chemopreventive agents has been discussed extensively 
mainly for the following advantages [8]: 1. As most of them are present in food that 
people are commonly consumed, they are easily accessible and cost-effective; 2. 
compared to most drugs used in chemotherapy, they have low or even none toxicity. 3. as 
has been reported by several clinical trials, many of the dietary compounds have already 
been proved to effect adjunctively with chemotherapy drugs. 
	  
Figure 7. A schematic diagram displaying the selective responsiveness of healthy 
population as well as cancer patients to chemopreventive agent. Generally, 
chemopreventive agents should be beneficial for every population. In cancer patients, it is 
feasible that combination regimens of chemopreventive agents and chemotherapeutic 
agents should be utilized. Moreover, modification of diet along with pharmological 
intervention should be considered for retarding and inhibiting cancer recurrence in post-
therapy cancer patients (Adapted from Mehta et al., 2010) [239]. 
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As has been reviewed previously, compared to other types of tumor the development 
of colorectal cancer usually requires a long time span, which provide us great opportunity 
for early detection and prevention [7]. Some evidence indicated that the recent increase in 
the survival rate of colorectal cancer was largely due to advances in early detection like 
colonoscopy and shift in the lifestyle, especially in the dietary pattern [2]. 
So far, there is a great number of studies in both cultured cell, animal models and 
human clinical trials that have supported the protective role of dietary compounds. For 
example, multiple natural polyphenols have been proved to be able to function against 
different type of cancers [9]. Generally, the compounds with chemopreventive properties 
can be categorized into several classes, for example, Carotenoid, Flavonoids, 
Isothiocyanates and omega-3 fatty acids. Pan et al. have reviewed the molecular 
mechanisms of chemopreventive effects of multiple natural dietary compounds on cancer 
[240]. 
2.4.2 Natural chemopreventive agents against CSC 
According to the CSC model, the lacking of ability to control the CSCs is the very 
reason for the failure of traditional chemotherapies and cancer relapse. Therefore, 
targeting the CSC population has become very promising for cancer prevention and 
therapy [241]. Generally, this would be achievable through strategies such as inducing of 
differentiation, inhibiting of self-renewal signaling pathways and sensitizing CSCs to 
chemotherapeutic agents [8].  
To make further progress in discovering and developing novel chemopreventive 
agents for effectively treatment of CSCs, it is of great importance to understand the 
mechanism through which the CSC can be affected by the dietary compounds. Though 
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still in the rudimentary stage, new findings in this field have been accumulated in a 
steady pace.  
Curcumin is a well-studied dietary polyphenol abundantly enriched in turmeric, a 
traditional Indian spice for curry preparation [242]. Multiple bioactive functions of 
Curcumin including anti-oxidant, anti-inflammatory effect have been studied [243]. Plus, 
results from pre-clinical trial test has support that preventing and delaying of the progress 
of cancer is one of the most promising properties of Curcumin [244]. As discussed above, 
several signaling pathways including WNT/β-catenin, Hedgehog and Notch play a central 
in self-renewal of CSC. The WNT/β-catenin signaling pathway is closely related to the 
maintenance of CSC in leukemia, breast, colon and lung cancers [245-247]. Recent 
finding have shown that curcumin was able to attenuate the WNT/β-catenin signaling in 
colon cancer cell lines, and also curcumin at 5µM would inhibited 50% of WNT 
signaling pathway in human breast cancer (MCF-7) [163]. Curcumin also impaired the 
WNT signaling and cell-cell adhesion pathway in human colon cancer cell (HCT-116), 
which resulted in apoptosis and G2/M cell cycle arrest [11]. It has also been reported that 
demethoxycurcumin (DMC) and bisedmethoxycurcumin (BDMC), natural analogues of 
curcumin, can inhibit the WNT signaling pathway through down regulating of the 
expression of transcriptional co-activator p300 in several human colon cancer cell lines 
[163]. Moreover, according to an analysis of gene transcription profile, the expression of 
Frizzled-1, a WNT receptor, can be suppressed by curcumin [248]. 
The Hedgehog pathway is another key relator in CSC self-renewal and development, 
which have been supported by the observation in leukemic, pancreatic and glioma CSC 
[151-153]. Particularly, by the using of Cyclopamine, a Hedgehog pathway inhibitor, the 
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self-renewal capacity of CSC derived by tumor sphere formation assay in glioma was 
significantly inhibited [153]. Curcumin also inhibit the hedgehog pathway in mouse 
derived TRAM-C2 prostate cancer cell as indicated by the decreased expression of Gli 
mRNA[166]. Data from another study showed that curcumin encapsulated in nano-
particular, can inhibit the expression of Gli mRNA [249]. In addition, hedgehog signaling 
also regulate cell proliferation by indirectly activation of cell-cycle related gene, such as 
cyclin D, and cyclin E, proteins that are related in G1-S phase transition [167].  
The Notch pathway is related to organ development by regulating cell proliferation 
and apoptosis [250]. At the level of 5µM and 10µM, curcumin can inhibit the Notch-1 
signaling pathway, resulting in apoptosis via the inactivation of transcriptional factor NF-
κB in pancreatic cancer cells [164].  Notably, the inhibitory effect of curcumin on the 
Notch1 pathway was also supported by the observation-reduced expression of Notch-1 
specific microRNAs such as miR-21 and miR-34 [165]. 
In addition, curcumin has also shown to regulate the STAT signaling pathways. As 
has been reviewed before, phosphorylation of STATs activate their function in regulating 
critical genes for cell cycle, cell proliferation, invasion and even maintenance of the 
tumor-initiating properties [232]. The findings of Lin et al. showed that the colorectal 
CSCs, characterized as ALDH+/CD133+ subpopulation, had higher level of STAT3 
phosphorylation [232]. Similarly, curcumin has also been proved to regulate the IL-6 
induced STAT3 phosphorylation in myeloma cancer cells [251]. Notably, compared to 
the curcumin itself, one of its analogues, GO-Y030 had much stronger effect in inhibiting 
the STAT3 phosphorylation and downstream gene such as cyclin D1, survivin and Bcl-
XL in colorectal CSC [215]. 
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Besides the effect on self-renewal pathways related to CSC biology, there are also 
some publications supporting that curcumin can also inhibit the tumor-sphere formation 
as well as the expression molecular surface makers [252-255]. The combination use of 
curcumin and the anti-cancer drug dasatinib, resulted in the decrease level of stem cell 
specific mRNA as well as the sphere formation ability; such combination of treatment, 
was in a synergistic manner [254]. Moreover, as resistance to cytotoxic drug is one of the 
major characters of CSC, it has been proposed that Curcumin can enhance the effect of 
anti-cancer therapeutics through multiple mechanisms [256, 257].   
Sulforaphane, found abundantly in cruciferous vegetables (e.g., broccoli) is another 
promising dietary compounds that bearing cancer chemopreventive property. A recent 
study by Li et al. showed that a relatively low dose of sulforaphane could inhibit the 
sphere formation in both MCF-7 and SUM159 breast cancer cells, with an IC50 ranging 
from 0.5-1µM [133]; more importantly, evidence also support such dose used in their 
study was physiological achievable by normal dietary consumption [258]. One of the 
possible mechanisms through which sulforaphane exerts its inhibitory effects on CSCs is 
by interfering with tumor necrosis factor-related apoptosis inducing ligand (TRAIL) -
activated NF-κB signaling [236]. Besides, various studies have reported that sulforaphane 
could also inhibit the Akt pathway in prostate and colorectal cancer [231, 233]. P13K/Akt 
pathway also plays a critical role in regulating breast stem cells [143]. 
Soy isoflavones, especially genistein, have also been reported to have potent anti-
cancer effect multiple cancer types [259]. Data have shown that by inhibiting Notch 
signaling pathway, genistein reduced the NF-κB activity, resulting in a cell growth 
inhibition and apoptosis in human pancreatic cancer cells [164, 235]. 
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Epidemiological studies have already supported that green tea consumption might 
have cancer preventive potential [260]. Results from several groups have shown that 
epigallocatechin-3-gallate (EGCG), the most abundant catechin found in green tea, could 
be a promising chemopreventive agent [261]. A recent study showed that the Wnt 
pathway was inhibited by the treatment of EGCG in human breast cancer cell [161]. 
Specifically, at the dose of 100µM, EGCG treatment lead to a 50% depression of WNT 
signaling pathway through the down-regulation of HMG box-containing protein 1(HBP1), 
a well- known WNT suppressor. With the inhibition of WNT, the tumorigenicity and 
invasiveness of breast cancer cell have been thereby weakened. Similar results were also 
observed by Zeng et al., who concluded that the high expression of WNT signaling 
pathway in breast cancer stem cell was crucial for the maintenance of their stemness 
[162]. So far many researchers have begun to connect the chemopreventive effective of 
EGCG to its function in suppressing WNT pathway in human breast CSC [10, 162].   
Vitamin D3, the active form of vitamin D, has been shown to induce apoptosis and 
cell cycle arrest in multiple types of cancer [160]. Recent studies have also reported that 
vitamin D3 was able to inhibit the cancer stem cell signaling pathways in solid tumor 
[262]. One the possible mechanisms through which vitamin D3 inhibit the WNT signaling 
was by inducing E-cadherin in colon cancer cells [160]. However, it is also worth 
mentioning that the inhibitory effect of vitamin D3 also varies on different cell types and 
specific cell line [262]. In conclusion, vitamin D3, it could be another therapeutic 
preventive dietary compound against CSCs. 
As been reviewed above, even though there are still limited reports regarding the 
inhibitory effect of natural dietary compounds against CSCs, many of them have already 
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shown be actively regulating the CSC related signaling pathways (e.g. self-renewal). 
Notably, some compounds, such as curcumin and sulforaphane, have shown a promising 
effect on CSCs at a very low concentration [133, 263]; such observation would provide 
us with the notion that the chemopreventive effects can be achievable through either 
normal “healthy” diet or dietary supplements. Overall, the study of the therapeutic/ 
preventive effect of natural bioactive compounds depends on a better understanding of 
the CSC biology, especially in the cross talk among multiples mediators in the 
maintaining of the “stemness”. Plus, for each specific agent of interest, a quantity-
function study should also be carried to determine the minimal dose required for the 
health-promoting effects. 
2.4.3 Polymethoxyflavones (PMFs) and cancer chemoprevention  
Due to their nutritional values and special flavor, citrus fruits are of great 
commercial importance. World-widely, the estimated number of citrus production in the 
major producing country was about 72 million metric tons in 2007 to 2008 (about 159 
billion lbs.) [15]. In the United States alone, of all the total citrus production (about 10.6 
million metric tons), about one third were used for juice production. With such a large 
amount of citrus used in the juice marker, considerably quantities of by-products such as 
peels, seeds are also been produced [264].  
Traditionally, since citrus peels are enriched with molasses, pectin, they have been 
used as cattle feed after a serial of processing; one the other hand, citrus peel is also a 
popular source of bioactive compound such as citrus flavonoids [15]. In fact, citrus peels, 
as a important traditional medical herb, have been long utilized as traditional medicine 
for treating diseases like stomach upset and hypertension [265]. Citrus flavonoids, 
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together with other polyphenolic components found in citrus peels have draw more and 
more attention due to their underlying anti-inflammation, anti-carcinogenesis health 
promoting effect [13].   
Generally, citrus flavonoids are classified into three different groups: the flavanone 
glycoside, the flavones glycoside, and polymethoxyflavones (PMFs) [13]. Interestingly, 
among all the citrus flavonoids, PMFs is the only one that almost exclusively found in the 
peels of sweet orange (Citrus sinesis) and mandarin oranges (Citrus reticulate) [18].   
 With more than 20 PMFs have been isolated and identified, Nobiletin (NBT), 
3,5,6,7,8,3´, 4´-heptamethoxyflavone (HMF) and tangeretin (TAN) are three major 
permethoxylated PMFs [264]. In tradition Chinese medicine, orange peels are usually 
prepared through heating and drying; thereby forms “aged orange peels”. Chemically, 
under the influence of such “aging process” and auto-hydrolysis during storage, NBT, 
HMF and TAN can be further converted to 5-hydroxy-6, 7,8,3´,4´-pentamethoxyflavone 
(5-demethylnobiletin, 5DN), 5-hydroxy-3,6,7,8,3´,4´-hexamethoxyflavone (5-HHMF), 
and 5-hydroxy-6,7,8,4´-tetramethoxyflavone demethyltangeretin (5-DT), respectively. 
These transformations involve the demethylation at the 5- position in A-ring of the basic 




Figure 8. Chemical structures of polymethoxyflavones (PMFs). (A) Chemical structure 
of nobiletin. (B) Nobiletin, 3,5,6,7,8,3´,4´-heptamethoxyflavone (NBT), and tangeretin 
are major abundant permethoxylated PMFs found in the peels of sweet oranges. During 
aging process, 5-hydroxy-6,7,8,3´,4´-pentamethoxyflavone (5DN), 5-hydroxy-
3,6,7,8,3´,4´-hexamethoxyflavone (5-HHMF), and 5-hydroxy-6,7,8,4´-
tetramethoxyflavone (5-HT) can be converted from nobiletin, HMF, and tangeretin, 
respectively (Adapted from Qiu et al., 2010) [18] 
	  
Increasing evidence have been merging to support multiple bioactive properties of 
PMFs, including anti-inflammatory [17], anti-carcinogenic [12, 18, 266-268], and anti-
oxidative [15]. Data from our recent studies showed that compared to their 
permethoxylated counterparts, demethylated PMFs exerted much more potency in terms 
of the biological functions as mentioned above [266-268]. 
Studies have shown that PMFs exhibit their anti-inflammatory function by inhibiting 





production of proteases of matrix-metallo-proteinase-9 (MMP-9) family and 
prostaglandin E2 (PGE2) in human synovial fibroblasts. Specifically, by downregulation 
of cyclooxygenase-2 (COX-2), which ultimately will lead to the inhibition of the matrix 
degradation of articular cartilage and pannus formation in osteoarthritis and rheumatoid 
arthritis [269]. Plus, a recent finding also showed that tangeretin also can suppress COX-
2 gene expression, and inhibited the UVB-induced transaction of NF-κB pathway in a 
dose-dependent manner [270]. 
Both in vitro and in vivo studies have that PMFs can be used as potential anti-
carcinogenesis agents, and most of the research have been focus on NBT and TAN, as 
that they abundantly found in citrus peels. A comparative study was conducted by 
Kandaswami et al., in which the growth inhibitory effects of various PMFs were 
evaluated [271]. Evidence supported that both NBT and TAN could inhibit breast and 
colon cancer growth by interfering the G1 phase cell cycle [14].  
Recent findings of our group also revealed that demethylated PMFs exhibited much 
stronger anti-cancer activities than their permethoxylated counterparts. Xiao et al. found 
that only demethylated PMFs, 5DN and 5HHMF were able to induce cell cycle arrest and 
apoptosis in human lung cancer cell [12]. Specifically, 5DN had much stronger inhibitory 
effect than tangeretin in human non-small cell lung cancer (NSCLC) cells by inducing 
G2/M cell cycle arrest and apoptosis [268]. In fact, among all the natural PMFs that we 
have studied, 5DN provided the strongest inhibitory effect [18]. Similar resulted were 
also obtained from both human breast [19] and leukemia cancer cells [272] studies, where 
3´-hydroxy-5, 6,7,4´-tetramethoxyflavone and 5HHMF exhibited much more potent 
effect than their permethoxylated counterparts, respectively.  
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When considering the efficacy of certain chemopreventive effect, it is important to 
take into account the physiological factors such as intracellular accumulation, 
metabolisms and excretion. Bioavailablity, by definition is the amount of drug or nutrient 
that can be absorbed to blood circulation and target tissues, is usually characterized by 
plasma concentration [273]. Four factors should be considered in order to determine the 
bioavailablity of certain agent: absorption, distribution, metabolism, and excretion 
(ADME) [274].  
As the key factor of bioavailability, absorption is influenced by both solubility and 
permeability of certain agents. Basically, compounds with high solubility and 
permeability would have the most absorption. When talking about the permeability, US 
Food and Drug Administration (FDA) provide us three absolute permeability criteria: 1. 
mass balance, absolute bioavailablity, or intestinal perfusion studies in human;  2. In vivo 
intestinal perfusion studies in animal model;  3. In vitro permeation experiments in 
passing through monolayer of cultured human intestinal cells such as Caco-2 cells [274]. 
Generally, our understanding of the PMFs has been based on the assumption that the 
multiple methoxy groups contribute to their high hydrophobicity. A study showed that 
after 4 hours of incubation more than 48% of nobiletin permeated to the bilateral side, 
indicating the high permeability and tendency to be accumulated in the intracellular 
compartment [275]. Other studies conducted in the SD male rats model by the same 
group further revealed that nobiletin is tend to accumulate in the mucous membrane and 




In a recent pharmacokinetic study, Manthey et al. compared the bioavailablity 
between NBT and TAN. According to their study, both NBT and TAN could be detected 
in rat serum for up to 24 hours after administration. However, compared to NBT, TAN 
showed much lower plasma concentration after been same amount of gavage [276].  
While the bioactivity of multiple PMFs including NBT and TAN have extensively 
reported as reviewed above, the study of the metabolic fate of PMFs in human body have 
not been conducted until recently. Basically, biotransformation plays a critical role in the 
biological activities of dietary compounds [277], and flavonoid compounds are no 
exceptions [278]. It has been suggested that after oral admiration, the metabolites 
generated through biotransformation might have even much potent biological activities 
[25]. A good example will be that Matthies et al. have found that after oral consumption, 
the anti-cancer effect of isoflavones such as daidzein was greatly depended on its 
biotransformation by phase I/ phase II enzymes as well as the influence of gut microflora 
[279].  
In light of the potential impact of the biotransformation on the health-promoting 
activities of PMFs, we have expended the current studies to the potential properties of 
metabolites of both nobiletin (NBT) and its natural demethylated counter-part, 5-
demethylated nobiletin (5DN).  
Recently, 3´-demethylnobileti (N1) [20], 4´-demethylnobileti (N2) [21], and 3´,4´-
didemethynobiletin (N3) [22] were reported as major metabolites from NBT and have 
recently been studied for their biological actions (Figure 9). Specifically, Li et al. have 
found that compared to the parent compound NBT, the metabolites including N1, N2 and 
N3 showed much potent anti-inflammatory effect in mouse macrophage RAW 264.7 [23]. 
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Their study further supported that the anti-inflammatory effect of N2 and N3 was closely 
associated with the suppressing of the iNOS and COX-2 gene-expression. Other studies 
also support that the metabolites of NBT have stronger anti-tumorgenesis activity [280]. 
According to our unpublished data, after oral feeding of NBT (1000 ppm) in mice model 
for 5 months, only about 2µM of NBT could be detected in mice colon mucosa; while 
majority of NBT had been transformed in three of its metabolites (N1, N2 and N3). This 
again indicated that in order to fully evaluate the biological impact of NBT on colorectal 
cancer, we need to include the metabolites in our study. 
Among all types of PMFs, 5-demethylated PMFs are a unique subclass, with 5-
demethylated nobiletin (5DN) as the most abundantly one that could be found in orange 
peel (especially, in aged orange peels) [18]. With the bioactivity of 5DN has already been 
studied by our group and other groups [12, 18, 19], the metabolites of 5DN, however, has 
been scarcely investigated. Recently, our group isolated the metabolites of 5DN 
identified 3 novel urinary metabolites of 5DN, namely, 5,3’-didemethylnobiletin (M1), 
5,4’-didemethylnobiletin (M2), and 5,3’,4’-tridemethylnobiletin (M3) (Figure 10) [25]. 
Notably, all three metabolites have showed stronger inhibitory effect in human colon 
cancer cells [25]. According to our unpublished data, after oral feeding of 5DN (1000 
ppm) in mice model for 5 months, while 5DN was still the most abundant that could be 
detected in the mice colon mucosa (about 15µM), a large portion of 5DN had been 
transformed into three of its demethylated metabolites (M1, M2 and M3). This indicated 
that it is also important to include the metabolites in our study in order to fully evaluate 





Figure 9.  The Biotransformation of NBT. After oral consumption of NBT, under the 
influence of phase I& II metabolisms, as well as the co-function of microbiota, NBT can 
be further transferred into three major metabolites: N1, N2 and N3. The only structural 









































Figure 10. The Biotransformation of 5DN. After oral consumption of 5DN, under the 
influence of phase I& II metabolisms, as well as the co-function of microbiota, 5DN can 
be further transferred into three major metabolites: M1, M2 and M3. The only structural 















 INHIBITORY EFFECTS OF NOBILETIN (NBT) AND ITS DEMETHYLETED 
METABOLITES ON COLON CANCER STEM CELLS 
 
3.1 Introduction  
Aggressive tumor growth, which is often linked with metastasis of malignant tumor 
to remote sites, contributes mostly to the poor prognosis for overall survival [110]. 
Colorectal cancer is the third leading cause of death in both men and women in the 
United States. Multiple barriers obstruct the successful colorectal cancer treatment. 
Among all the challenges, tumor reoccurrence and metastasis are two major survival-
influencing factors of colorectal cancer treatment. For example, up to 40% of colorectal 
cancer patients who present with stage II or III colorectal cancer treatment will recur after 
primary treatment [1]. In colorectal cancer treatment, despite the rapid advances in 
chemotherapeutic drugs, 89% patients with metastatic disease cannot survive [2]. All 
these indicate the failure of conventional interventions including both radio- and chemo- 
therapies. Thus, it is of great important for us to develop novel and effective strategies for 
the control of colorectal cancer.  
Recently, there is increasing experimental evidence supporting that the existence of 
a small sup-population of tumorigenic cells, namely, cancer stem cells (CSCs), are 
responsible for the tumor-initiation, metastasis and recurrence after conventional therapy. 
Multiple studies have been focused on the relevance between CSCs and colorectal cancer, 
which support the center role of CSCs in the overall poor prognosis and therapy failure in 
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colorectal cancer [5, 6, 60, 115]. Targeting CSC compartment, therefore, become a 
promising solution for both the prevention and /or treatment of colorectal cancer [241]. 
Epidemiological and dietary interventions studies in both animal and human models 
have suggested the positive role of many dietary components in inhibiting, reversing 
tumor development in different type of cancers [9]. So far, several of the dietary agents 
have also been shown to interfere with the function of CSCs [10]. Generally, this would 
be achievable by strategies such as inducing of differentiation, inhibiting of self-renewal 
signaling pathways and sensitizing CSC to chemotherapeutic agents [8]. For example, 
curcumin was reported to be able to impair the WNT signaling and cell-cell adhesion 
pathway in human colon cancer cell (HCT-116), which resulted in apoptosis and G2/M 
cell cycle arrest [11]. 
Polymethoxyflavones (PMFs) are a group of compounds that are almost exclusively 
found in the peels of citrus fruit [12]. So far, PMFs have been found to have wide 
spectrum of health promoting effect including anti-inflammation and anti- carcinogenesis 
[13]. Previously, as one of the major permethoxylated PMFs, nobiletin (NBT) has been 
reported to have various biological properties such as anti-tumorgenesis, anti-
inflammation and oxidative stress [14-17]. In fact, when considering the efficacy of 
certain bioactive compound, it is of great importance that one should also take into 
account of physiological factors such as metabolism; in other word, as a result of 
biotransformation, the metabolites would deserve more attention since many of them 
might have even more significant activities than the parent compound [25]. In fact, 3´-
demethylnobileti (N1) [20], 4´-demethylnobileti (N2) [21], and 3´,4´-didemethynobiletin 
(N3) [22] were already been identified as major metabolites from NBT and have recently 
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been studied for their biological actions. Evidence have supported that metabolites of 
NBT, exerted much stronger anti-inflammatory [23] and anti-mutagenic [24] effect 
compared to NBT.  Our recent progress in the biotransformation and tissue distribution 
(unpublished) showed that in order to fully evaluate the biological impact of NBT on 
colorectal cancer, it is critical to include NBT as well as its metabolites in this study. 
Herein, in this study, for the first time we investigated the inhibitory effect of NBT 
and three of its demethylated metabolites in human colorectal CSCs.  
3.2 Materials and methods 
3.2.1 Treatment and cell culture  
HCT-116 and HT-29 Human colon cancer cell lines were obtained from American 
Type Cell Collection (ATCC, Manassas, VA, USA), and maintained in RPMI 1640 
media (Media tech) supplemented with 5% heat-inactivated fetal bovine serum and 
100U/mL of penicillin and 0.1mg/mL of streptomycin at 37°C with 5% CO2 and 95% air. 
Cells were maintained in subconfluent culture and media were changed every 3–4 days. 
All cells used in experiments were between 4 and 20 passages. NBT and their 
demethylated metabolites were isolated and identified as previously described [12, 264, 
281]. DMSO was used as vehicle to deliver NBT and demethylated metabolites to the 
cells. The final concentration of DMSO in all experiments was 0.1% v/v in cell culture 
media. 
The sphere culture was carried out in serum free DMEM/F12 medium (Life 
Technologies). Briefly, the serum free medium (SFM) was the supplemented with 1×B27 
(Life Technologies), 20ng/ml EGF (Life Technologies), 20ng bFGF (Life Technologies), 
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5 µg/ml human insulin (Sigma-Aldrich), 100U/ml of penicillin and 0.1mg/ml of 
streptomycin.  
3.2.2 Isolation of colon cancer stem cell and tumor sphere formation assay 
Singles cells obtained from HCT-116 cell line were plated in ultra-low attachment 
24-well plates (Corning, Lowell, MA, USA) at a density of 12000 viable cells per well in 
triplicate. Cells were grown in SFM as described above at 37°C with CO2 and 95% air. 
Right after seeding, cells were treated with 12.5-50µM of NBT and its demethylated 
metabolites for 7 days. After 7 days, tumor sphere were observed under microscope. For 
counting of spheres, cells were collected and transferred onto collagen-coated dishes 
respectively and cultured in RPMI 1640 medium supplemented with 5% FBS. In 
approximately 24h, tumor sphere were adhered, then stained with crystal violet and 
counted. 
Secondary tumor sphere formation: for the passage of tumor sphere, single cells 
suspension was first obtained from primary tumor sphere by brief trypsinization. Then 
single cells from primary spheres were plated at the density of 2000 cell per well in 
triplicate. The secondary tumor spheres were grown, treated, harvested and counted as 
described above.  
In order to compare the sphere-forming potential of primary and secondary test, the 
results were further normalized as number of tumorspheres formed per 1000 seeding cells. 
3.2.3 Cell cycle analyses 
Cells from HCT-116 and HT-29 cell line were seeded as single cell in 6-well 
suspension plates in SFM at a density of 12000 cells per well. Right after seeding, cells 
were treated with different concentrations of NBT and demethylated metabolites. After 7 
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days, the whole content of each well were collected by brief trypsinization (0.25% 
trypsin-EDTA; Sigma-Aldrich). Cell pellets were washed with 1mL of ice-cold PBS and 
then re-suspended in 1mL of 70% ethanol in -20°C overnight. After centrifugation 
(1600g, 1 min), the supernatant was removed and cells were incubated with 0.3mL of 
PBS containing 30 µg RNase (Sigma-Aldrich) and 3µg propidium iodine (Sigma-Aldrich) 
for 30min at room temperature. Single-cell suspension was generated by brief 
trypsinization. Cell cycle was analyzed using a BD LSR II cell analyzer at the analytical 
cytometry facility (University of Massachusetts Amherst), and data were processed using 
Modifit LT software. 
3.2.4 Detection of apoptosis 
HCT-116, HT-29 cells were seeded and treated exactly the same as described in cell 
cycle analyses above. After 7 days of incubation, apoptotic cells were quantified by 
Annexin V/propidium iodide (PI) double staining assay. Annexin V/PI staining was done 
using apoptotic detection kit (BioVision, Mountain View, CA, USA) following the 
manufacturer’s instruction. Briefly, the content of each well were collected and disrupted 
by brief trypsinization, and then washed with ice cold PBS. After another wash with 
binding buffer, cells were suspended in 0.3 mL Annexin V binding buffer containing 
Annexin V and PI, and incubated for 5min at room temperature before analysis by flow 
cytometer. Early apoptotic cells were identified as Annexin V-positive/PI-negative cells, 
while late apoptotic/necrotic cells were identified as Annexin V-positive/PI-positive cells 




3.2.5 Immunoblotting  
After treatment with serial concentration of NBT and its metabolites (namely, N1, 
N2 and N3) for 7 days, whole cell lysate will be obtained following method as previously 
described [268]. Briefly, suspended spheroid cells will then be collected and washed with 
ice- cold PBS. Cells will then be incubated on ice for 10 min in lysis buffer (Cell 
signaling, Beverly, MA, USA) supplemented with cocktails of protease inhibitor (1:100), 
phosphatase inhibitor I (1:100), and phosphatase inhibitor II (1:100) (Boston Bio 
products, Boston, MA, USA). After sonication (4 seconds, 4 times), cells will be 
incubated for 20 mins on ice and followed by centrifugation at 14,000 rpm using a bench 
top Eppendorf centrifuge for 20 mins at 4°C. Supernatants will be collected as whole cell 
lysates. Proteins will be quantified by BCATM protein assay kit (Pierce Biotechnology, 
Rockford, IL, USA), and 50-150 µg of proteins will be resolved either by 8%, 12% or 15% 
SDS-polyacrylamide gel electrophoresis and then transferred to nitrocellulose membrane. 
The membrane containing the transferred protein will be blocked in blocking buffer (5% 
nonfat dry milk, 1% Tween-20 in 20 mM Tris-buffered saline, pH 7.4) for 2 h at room 
temperature, and then incubated with appropriate primary antibodies in blocking buffer 
overnight at 4°C. After incubation with appropriate secondary antibodies for 2 h at room 
temperature, the membranes will be washed with Tris buffer containing 0.5% of Tween-
20, and then be visualized using enhanced chemiluminescence kit (Boston Bio products, 
Ashland, MA, USA). Antibodies for Cyclin D1, p21Cip1/Waf1, p53,  RIP3 and cleaved poly 
ADP ribose polymerase (PARP) will be obtained from Cell Signaling Technology 




3.2.6 Statistical analysis  
All data were presented as mean ± SD. Student’s t-test was used to determine the 
mean difference between two groups. Analyses of variance (ANOVA) model was used 
for the comparing the differences among more than two groups.  
3.3 Results 
3.3.1 NBT and its demethylated metabolites inhibited tumorsphere formation in 
colon cancer stem cells. 
To determine whether the treatment of NBT and their demethylated metabolites 
would influence the proliferation of colorectal CSCs, we conducted tumor sphere 
formation assay on spheroid cells derived from both HCT-116 and HT-29 cell lines 
(Figure.11 and Figure. 12). Specifically, HCT-116 and HT-29 cells were seeded as single 
cell in Serum-free medium (SFM) and treated with NBT (12.5µM- 50µM) or three 
demethylated metabolites: N1 (12.5µM-50µM), N2 (12.5µM-50µM) and N3 (12.5µM-
50µM). The tumor sphere-forming potential of both primary and secondary CSCs were 
analyzed. For CSCs derived from HCT-116 cell line (Figure. 11 A), the primary 
tumorsphere forming frequency in the control group got increase from about 0.4% (4 
tumorspheres formed per 1000 seeding cells) to about 1.7% (17 tumorspheres formed per 
1000 seeding cells) in the secondary test, this further supported the notion that sphere-
culturing in SFM as an effective tool in enriching the CSC subpopulation. Compared to 
the control group, the sphere-forming ability following each treatment was significantly 
impaired in a nearly dose-dependent manner. For example, the treatment of NBT at 
12.5µM resulted in a nearly 50% percent of inhibition of primary tumorsphere, and at 
50µM, the inhibitory effect got increased to almost 66%. Then we compared the 
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inhibitory effect of three of its demethylated metabolites (N1, N2 and N3) with that of 
NBT: for the primary tumorsphere test, only N3 (50µM) showed stronger inhibitory 
effects compared to the parent compound, NBT (50µM); as for the secondary test, the 
treatment of N1 (12.5µM), N2 (50µM) and N3 (50µM) was showed to be more potent 
than their NBT-treating counterparts. For example, N3 (50µM) led to a 100% inhibition 
in secondary tumor sphere formation, while NBT (50µM) only resulted in a 60% 
reduction. Plus, such inhibition of sphere-forming potential was also observed as the 
reduction of tumorsphere sizes (Figure 11 B). 
Similar pattern was also observed in the tumorsphere-forming ability of CSCs 
derived from HT-29 cell line (Figure 12 A). Compared to the control group, the treatment 
of NBT and its demethylated metabolites (N1, N2 and N3) resulted in a significant 
decrease in the sphere-forming potential in both primary and secondary test. Then we 
compared the effect of three demethylated metabolites (N1, N2 and N3) with that of NBT: 
for the primary test, N2 (12.5µM, 25µM), N3 (12.5-50µM) showed significantly stronger 
effect than those NBT-treating group; for the secondary test, the treatment of N1 (12.5µM, 
50µM), N2 (12.5µM) and N3 (12.5µM, 50µM) showed to be more potent than the NBT-
treating counter-part. Plus, such inhibitory effects were also observed in the reduction of 






Figure 11.  The treatment of NBT and its demethylated metabolites (N1, N2 and N3) 
inhibit the tumorsphere formation of colorectal CSCs derived from HCT-116 cell line. (A) 
For the primary tumorsphere formation assay, single cells from HCT-116 cell line were 
seeded in 24-well ultra-low attachment plates (12000 cells per well); for the secondary 
tumorsphere formation, single cells obtained from the primary tumorspheres as described 
in Material and Methods were seeded in 24-well ultra-low attachment plates (2000 cells 
per well,) in triplicate in a serum-free (SFM) medium. Right after seeding, CSCs were 
treated with NBT (12.5µM to 50µM) and three of its demethylated metabolites: N1, N2 
and N3 (12.5µM to 50µM). After 7 days, primary/ secondary tumorspheres were 
collected and counted. All data represent mean ± SD, * indicated the statistical 
significance of each treatment in comparison with the control (DMSO) group, as *p<0.05, 
**p<0.01, *** p<0.001; # indicated the statistical significance of metabolites-treating 
groups in comparison with the NBT-treating group, as #p<0.05, ##p<0.01, ###p<0.001. 
(B) Tumorsphere culture demonstrating sphere-formation of colorectal CSCs derived 
from HCT-116 cell line following the treatment with NBT and its demethylated 





Figure 12. The treatment of NBT and its demethylated metabolites (N1, N2 and N3) 
inhibit the tumorsphere formation of colorectal CSCs derived from HT-29 cell line.  
(A) For the primary tumorsphere formation assay, single cells from HT-29 cell line were 
seeded in 24-well ultra-low attachment plates (12000 cells per well); for the secondary 
tumorsphere formation, single cells obtained from the primary tumorspheres as described 
in Material and Methods were seeded in 24-well ultra-low attachment plates (2000 cells 
per well,) in triplicate in a serum-free (SFM) medium. Right after seeding, CSCs were 
treated with NBT (12.5µM to 50µM) and three of its demethylated metabolites: N1, N2 
and N3 (12.5µM to 50µM). After 7 days, primary/ secondary tumorspheres were 
collected and counted. All data represent mean ± SD, * indicated the statistical 
significance of each treatment in comparison with the control (DMSO) group, as *p<0.05, 
**p<0.01, *** p<0.001; # indicated the statistical significance of metabolites-treating 
groups in comparison with the NBT-treating group, as #p<0.05, ##p<0.01, ###p<0.001. 
(B) Tumorsphere culture demonstrating sphere-formation of colorectal CSCs derived 
from HT- 29 cell line following the treatment with NBT and its demethylated metabolites.	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3.3.2 NBT and its demethylated metabolites induced apoptosis (necroptosis) in colon 
colorectal stem cells 
We next examined the extent to which cell death pathways such as apoptosis and/or 
necroptosis contributed to the inhibitory effect of NBT and its demethylated metabolites 
on tumorsphere forming capacity of CSCs as we have demonstrated in Chapter 3.3.1. 
For CSCs derived from HCT-116 cell line (Figure 13), the treatment of NBT (25µM) 
showed no significant apoptosis (or necroptosis) inducing effect; while for N1 (25µM), 
N2 (25µM) and N3 (25µM) significantly induced apoptosis (necroptosis) compared to 
both control and the NBT- treating group. For example, N1 (25µM) resulted in one fold 
of increase (from 5.8% to 11.4%) in the total apoptotic ( or necroptotic) population 
compared to the control group. Notably, N3 (25µM) increased total apoptotic (or 
necroptotic) population by 2.6-fold.  
Similar pattern were also observed in the CSCs derived from HT-29 cell line (Figure 
14). Particularly, compared to the control group, all treatments led to signify of induction 
of apoptotic (necroptotic) cells. For example, NBT (25µM) increased the total apoptotic 
(necroptotic) cells by (from 4.4% to 13.7%) by 3.1-fold; N2 (25µM) also increased the 





Figure 13. The treatment of NBT and its demethylated metabolites induced apoptosis (or 
necroptosis) in CSCs derived from HCT-116 cell line. (A) HCT-116 cells were seeded as 
single cell in 6-well suspension plates in SFM at a density of 12000 cells per well. Right 
after seeding, cells were treated with NBT (25µM) and demethylated metabolites N1 
(25µM), N2 (25µM)  and N3 (25µM). After 7 days, apoptotic cells were quantified by 
Annexin V/propidium iodide (PI) double staining assay as described in Materials and 
Methods. FITC high/ PI low cells were defined as early apoptotic cells, FITC high/ PI high cells 
were defined as late apoptotic (or necroptotic) cells. All data represent mean ± SD, * 
indicated the statistical significance of each treatment in comparison with the control 
(DMSO) group, as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical 
significance of metabolites-treating groups in comparison with the NBT-treating group, 
as #p<0.05, ##p<0.01, ###p<0.001. (B) The distribution pattern of CSCs (HCT-116) 





Figure 14.	  The treatment of NBT and its demethylated metabolites induced apoptosis (or 
necroptosis) in CSCs derived from HT-29 cell line. (A) HT-29 cells were seeded as 
single cell in 6-well suspension plates in SFM at a density of 12000 cells per well. Right 
after seeding, cells were treated with NBT (25µM) and demethylated metabolites 
N1(25µM), N2(25µM)  and N3 (25µM). After 7 days, apoptotic cells were quantified by 
Annexin V/propidium iodide (PI) double staining assay as described in Materials and 
Methods. FITC high/ PI low cells were defined as early apoptotic cells, FITC high/ PI high cells 
were defined as late apoptotic (or necroptotic) cells. All data represent mean ± SD, * 
indicated the statistical significance of each treatment in comparison with the control 
(DMSO) group as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical significance 
of metabolites-treating groups in comparison with the NBT-treating group, as  #p<0.05, 
##p<0.01, ###p<0.001. (B) The distribution pattern of CSCs (HT-29) following the 




3.3.3 NBT and its demethylated metabolites caused cell-cycle redistribution in 
colorectal colon cancer cells  
We next investigate the possible effects of NBT and its demethylated metabolites on 
the cell cycle distribution of CSCs. Theoretically, the quiescence (or slow cycling) nature 
of CSCs would make most of them stay in the G0/G1 phase [122] .  
For CSCs derived from HCT-116 cell line (Figure 15), more than 80% of cells in the 
control group were found in the G1/G0 phase. All the treatment decreased the cell 
distribution in G1/G0 phase compared to the control group. For example, the treatment of 
N3 (25µM) decreased the cells distribution in G1/G0 phase from 81% to 72%; Then we 
compared the effect of three metabolites with that of NBT: compared to the NBT-treating 
group, N1 (25µM) and N3 (25µM) both significantly decreased the cell population in 
G1/G0 Phase. Similar patterns were also observed in CSCs followed by the treatment of 
NBT (25µM) or its metabolites, where the cell cycle distributing was significantly altered. 
For example, compared to the control group, the treatment of N3 (25µM) decreased the 
cell distribution in G0/G1 phase from 70% to 63%. However, compared to the NBT-
treating group, none of the groups treated with metabolites (N1, N2 and N3) showed 
higher potency.  
Similar pattern was also been observed in CSCs from HT-29 cell line (Figure 16). 
About 70% cells were in the G0/G1 phase in the control group; the treatment of NBT 
significantly decreased the number of cells in the G0/G1 phase, while all the three 





Figure 15. The treatment of NBT and its demethylated metabolites altered the Cell Cycle 
distribution of CSCs derived from HCT-116 cell line. (A) HCT-116 cells were seeded as 
single cell in 6-well suspension plates in SFM at a density of 12000 cells per well. Right 
after seeding, cells were treated with NBT (25µM) and demethylated metabolites N1 
(25µM), N2 (25µM) and N3 (25µM). After 5 day, cells were collected and subjected to 
cell cycle analyses as described in Material and Methods. All data represent mean ± SD, 
* indicated the statistical significance of each treatment in comparison with the control 
(DMSO) group as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical significance 
of metabolites-treating groups in comparison with the NBT-treating group, as  #p<0.05, 
##p<0.01, ###p<0.001. (B) Cell cycle distribution of CSCs (HCT-116) following 




Figure 16. The treatment of NBT and its demethylated metabolites altered the Cell Cycle 
distribution of CSCs derived from HT-29 cell line. (A) HT-29 cells were seeded as single 
cell in 6-well suspension plates in SFM at a density of 12000 cells per well. Right after 
seeding, cells were treated with NBT (25µM) and demethylated metabolites N1 (25µM), 
N2 (25µM) and N3 (25µM). After 5 day, cells were collected and subjected to cell cycle 
analyses as described in Material and Methods. All data represent mean ± SD, * indicated 
the statistical significance of each treatment in comparison with the control (DMSO) 
group as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical significance of 
metabolites-treating groups in comparison with the NBT-treating group, as  #p<0.05, 
##p<0.01, ###p<0.001. (B) Cell cycle distribution of CSCs (HT-29) following treatment 





3.3.4 NBT and its demethylated metabolites inhibited the growth of colorectal CSC 
by regulating key proteins related to apoptosis, necroptosis and cell cycle.  
In order to elucidate the molecular mechanisms governing the inhibitory effects of 
NBT and its demethylated metabolites (N1, N2 and N3) on CSCs from both HCT-116 
and HT-29 cell line, we analyzed the effects of treatments on some key proteins in 
regulating cell cycle and apoptosis by immunoblotting analysis as described in chapter 
3.2.5.  
To confirm the apoptosis-inducing effect of our treatment as described in chapter 
3.2.3, we examined their effects on poly ADP ribose polymerase (PARP) and p53 (for 
possible p53-dependent apoptosis). According to our results (Figure 17), for CSCs 
derived from HCT-116, NBT and all its metabolites increased the level of p53, with N1 
(25µM) having the strongest effect. While among all of our treatments, only N1 (25µM) 
signify increased the expression of cleaved PARP, which is the indicator of apoptosis. 
For cells derived from HT-29, it was found that only N3 (25µM) resulted in the 
significant increase of P53; on the other hand, dramatic increasing in the level of cleaved 
PARP confirmed that occurrence of apoptosis following our treatment. 
 In cell cycle arrest, P21 is transcriptionally regulated by p53. Plus, p21 has also 
been found to control entry into quiescence and maintaining of the quiescent state [282]. 
According to our result (Figure 17), in CSCs derived from HCT-116, there was a 
significant increase in the level of p21 followed by our treatment; however, as for CSCs 
derived from HT-29, the opposite trend was observed.  
Cyclin D1 plays a central role in promoting the entry into the cell cycle, high level 
of cyclin D1 is required for the G1/S transition [283]. According to our results (Figure 17) 
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increased levels of cyclin D1 were detected following the treatments in CSCs derived 
from both HCT-116 and HT-29 cell line. This could be further used to confirm that our 
treatments were able to force CSCs to re-enter cell cycle.  
	  
	  
Figure 17. The treatments of NBT and its demethylated metabolites (N1, N2 and N3) in 
modulating key proteins regulating apoptosis and cell cycle. Immunoblots displayed the 
treatment of NBT (25µM) and three of its metabolites: N1 (25µM), N2 (25µM) and 
(25µM) on p21cip1/Waf1, p53, cleaved PARP and Cyclin D1 on CSCs derived from HCT-
116 and HT-29. The numbers under the blots represent band intensity (normalized to β-
actin, means of three independent experiments). The standard deviations (all within ± 15% 
of the means) were not shown. β- actin served as an equal loading control.	  
	  
Besides apoptosis, necroptosis is also regarded as an important programmed 
pathway way, especially when apoptosis fails for multiple reasons. Therefore, in our 
study, we also test that whether our treatments could result in the level change of the 
RIP3, one of the markers of the necroptosis pathway. As shown in Figure 18, for CSCs 
derived from HCT-116, the treatment of NBT (25µM), N1 (25µM) and N3 (25µM) 
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increased the level of RIP3; while for CSCs derived from HT-29, only NBT (25µM) and 
N2 (25µM) induced the increase in RIP3.  
	  
Figure 18. Effects of NBT and its three demethylated metabolites (N1, N2 and N3) on 
the expression of RIP3, one of the key regulators of necroptosis. Immunoblots displayed 
the treatment of NBT (25µM) and three of its metabolites: N1 (25µM), N2 (25µM) and 
(25µM) on one of the key molecular marker of necroptosis, RIP3. The numbers under the 
blots represent band intensity (normalized to β-actin, means of three independent 
experiments). The standard deviations (all within ± 15% of the means) were not shown.β- 




3.4 Discussion  
Currently, NBT, as one of the major permethoxylated PMFs has been reported to 
have various biological properties such as anti-tumorgenesis, anti-inflammation and 
oxidative stress [14-17]. Plus, in light of the importance of biotransformation in the 
understanding the overall function of certain bioactive compound, attention have also 
been focused on three of the demethylated metabolites of NBT, namely, N1, N2 and N3.  
Recently, the metabolites of NBT have been studied for their biological properties. 
Evidence have supported that metabolites of NBT, exerted much stronger anti-
inflammatory [23] and anti-mutagenic [24] effect compared to parent compound . So far, 
there has been no publish on NBT and its metabolites targeting the CSCs, which is 
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believed to be the fundamental factors that the hinters the effectiveness of current 
preventive/ therapeutic strategies for cancer control. 
 In vitro tumor sphere formation has already been proved to be an effective tool in the 
study of CSCs [85]. In this study, we determined the effects of NBT and their metabolites 
in both primary and secondary tumor formation. According to our results  we found that 
the frequency of sphere-forming cells in the secondary culture was almost 3-folds as high 
as the frequency in the primary culture, which further confirmed the “CSCs-enriching” 
function of the suspension sphere culture. There are evidence supporting that such 
spheroid- forming cells has significant higher “tumor-initiating” ability in the transgenic 
mouse model than cells cultured with conventional methods [84, 91, 92]. According to 
the result from the tumorsphere formation study, we found that for both CSCs derived 
from HCT-116  and HT-29, the treatment of NBT or their demethylated metabolites 
could significantly impair the in vitro sphere-forming ability. Furthermore, prolonged 
treatment of NBT or their metabolites also resulted in the induction of apoptotic cells as 
well as a shift the cell cycle redistribution in CSCs derived from both cell lines. 
Interestingly, we have observed that for each cell line, the level of responses differs when 
cells were subjected to different treatment (NBT or metabolites), generally, it was 
observed that metabolites had stronger effects on the cells than the parent compound; on 
the hand, results also showed that CSCs derived from the two cell line, responded 
differently when subjected to the same treatment. This may indicate that the phenotype 
difference may contribute to the different cellular-sensitivity to our treatments. 
So far, with several research have been focused on the regulation of self-renewal, 
proliferation and differentiation of CSCs, studies of cell death pathways including 
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apoptosis and necroptosis are still quite limited [168]. In this study, we examined whether 
NBT and their demethylated metabolites exert the inhibitory effect on CSCs by 
regulating some of the key modulators in apoptosis and cell cycle distribution 
(quiescence maintaining).  
The cleavage of PARP facilitates cellular disassembly and serves as a marker of 
cells undergoing apoptosis [284]. Our results in immunoblotting showed that within each 
cell line we have test, the treatment of NBT or metabolites resulted in the increased level 
of cleaved -PARP compared to the control group. Such increase in cleaved PARP can be 
used to further support our observation in the apoptosis test by flow cytometry. 
The tumor suppressor, p53, has been implicated in a variety of cellular processes 
and regarded as the “guardian of the genome’’ in cells. It exerts its function by inducing 
apoptosis and growth arrest. According to our results, treatment of NBT and metabolites 
resulted in the up-regulation of p53 in CSCs derived from HCT-116. This may indicate 
that the inhibitory effect of our treatment was p53 -dependent in CSCs derived from 
HCT-116 cell line.  To our surprise, for CSCs derived from HT-29 cell line, the level of 
total p53 protein almost kept unchanged following our treatment. A possible explanation 
would be that rather than a elevation in the total p53 level, the treatment could lead to the 
increase in the serine phosphorylation level of p53. In a study using curcumin to treat 
HT-29 cells, such high level of the serine phosphorylation of p53 (total p53 remains 
unchanged) was shown to be able to down-regulate the anti-apoptotic factor, Bcl-2 and 
up-regulating the pro-apoptotic factor Bax, thereby decreasing the Bcl-2/Bax ratio and 
disposing to apoptosis [285].  
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Recently, the role of p53 in cancer stem cell has been discussed in detail by Aloni-
Grinstein et al.[286]. Particular, it has been proposed that p53 can also function as a 
differentiation inducer in various cell types, which place it as an attractive candidate for 
differentiation therapy in control of CSCs [286]. According to our result in this study, 
increased level p53 was observed in CSCs derived from HT-116 cell line. Though 
evidence is still vastly lacked, this might also be novel for our understanding of the 
mechanism behind the inhibitory effect of NBT and metabolites on colorectal CSCs. 
The CDK inhibitor  p21CIP1/ WAF1, is a member of Cip/Kip family and responsible for 
both p53 dependent and p53-independent cell cycle arrest [287]. During the p53- 
dependent cell cycle arrest, p21 served as a down stream transcriptional targes of p53; 
increased levels  of p53 would also result in increased level of p21CIP1/ WAF1, which will in 
turn contributes to cell cycle arrest. As for our study, such pattern (increased p21CIP1/ WAF1, 
plus increased p53 protein level) was observed in CSCs derived from HCT-116 followed 
by the treatment of NBT and metabolites. This further supported that NBT and 
metabolites might probably exert their function through p53- dependent p21 mediated 
pathway.  
Evidence supported that disruption of cell cycle inhibition may also contribute to the 
very nature of CSCs, especially in breaking the balance between the self-renewal and 
differentiation, which lead to the deregulated self-renewal of CSCs [203]. Theoretically, 
the quiescence (or slow cycling) nature of CSCs would make most of CSCs stay in the 
G0/G1 phase. As has been discussed in chapter 2.3.2, quiescence is one of the major 
mechanisms contributing the therapy resistance of CSCs. Particularly, G0 phase is 
viewed as either an extended G1 phase, where the cell is neither dividing nor preparing to 
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divide, or a distinct quiescent stage that occurs outside of the cell cycle [122]. It has also 
been proposed that, targeting p21 or its down stream target may be an effective means to 
force quiescent CSCs to cycle and thereby be more susceptible to chemotherapies and 
undergo apoptosis.  As for our cell cycle analysis, we found that for both control and test 
group, more than 80% of total population of CSCs was in the G0/G1 phase, which is not 
usual in our study of the bulk of cancer cells (data not shown). This could be an 
indication that majority of cells in the suspension culture are CSCs. According to our 
observation in the cell cycle detection and immunoblotting, a decrease in G0/ G1 phase 
cell population for both cell lines as well as a reduced levels of p21 in HT-29 were 
observed; Cyclin D1 plays a central role in the entry of cell-cycle, particularly, high level 
of cyclin D1 expression can be an indicator G1/S transition [283]. According to our 
results, in CSCs derived from both HCT-116 and HT-29 cell line, all our treatments 
(NBT and metabolites) led to increased expression cyclin D1, which were in line with our 
observation in the cell cycle distribution.  Still, further evidence are still needed to 
connect the inhibitory of our treatment on CSCs and the “re-enter” into cell cycle.  
Besides apoptosis, evidence has been accumulated supporting that apoptosis is not 
the only mechanisms that could control the cell death. Specifically, necroptosis, also 
known as the programmed necrosis, has gained more attention in recent years. Besides 
the necrosis-like morphology changes, necroptosis are also believed to maintains part of 
the apoptotic features as apoptosis [188, 189]. In our research, we also hypothesize that 
necroptosis could be another factor contributed to the inhibitory effects of NBT and 
metabolites on colorectal CSCs. Specifically, our hypothesis was based on the following 
reasons: 1. Possible limitation exists for our methods in “apoptotic” cell detection. Time-
	  
83	  
lapse imaging, which allows monitoring of morphological changes in individual cells in a 
dynamic and comparative manner, is so far the most effect way to reveal the differences 
between apoptosis and necrosis (necroptosis) [288]. However, during our research, cells 
were analyzed by flow fluorocytometry for exposure of phosphatidylserine (PS, 
characterized by the binding of FITC) and changes in permeability (uptake of propidium 
iodide, characterized by binding of PI). Notably, in apoptosis, membrane changes will 
lead to a rapid PS exposure, while the permeability change will be lagged behind [288] . 
Such phenomena result in the steady shift from early phase apoptosis (PI low / FITC high 
cells) to late phase apoptosis (PI high / FITC high cells); for necroptosis (necrosis), PS 
exposure overlaps with the changes with permeability changes, which result in the rapid 
shift of cell population from lower left corner (PI low / FITC low cells) to the upper right 
corner (PI high / FITC high cells). Therefore, in our research, since we only tested the cell 
distribution pattern at the end of 7- day incubation, the upper right cells preciously 
defined as “late phase apoptosis” cells, could also be cells went through “necrosis 
(necroptosis)”; 2. It has been reported that necroptosis is an alternative cell death pathway 
especially when apoptosis cannot be archived because of the ATP failure (apoptosis is the 
most energy-consuming process since that it requires the activation of multiple caspases 
and the formation of apoptosome) [200-202]. As in our study, CSCs were derived in 
serum free medium (SFM) supplemented with growth factors (see Material and Methods) 
and cultured extensively for 7 days. Such condition would result in the possible “energy 
starvation” thus necroptosis could be accounted as an alternative death pathway involved. 
3. One of the key characters of CSC is higher apoptosis-resistance compared to the non-
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CSC counterpart [289], this could be another reason besides ATP failure that can make 
necroptosis an alternative explanation for the inhibitory effect of our treatment.  
To test hypothesis, we test the expression of the RIP3, one of the key molecular 
regulators of necroptosis [192, 193] by immunoblotting. It was shown that our treatment 
caused increased RIP3 level in CSCs from both cell lines: for HCT-116 derive CSCs, 
NBT, N1 and N3 result in the increasing in RIP3 while for CSCs derived from HT-29, it 
was the treatments of NBT, N1 and N3 resulted in the elevated level of RIP3 expression. 
Evidence have been supporting that caspase 8 plays opposite roles in cross-talk between 
apoptosis and necroptosis: TNF activate apoptosis by triggering a series of molecular 
events which eventually lead to the activation of caspase 8; while in necroptotic pathway, 
the function of caspase 8 is disrupted or even inhibited [191]. Therefore, we will further 
confirm our observation by assessing the level of caspase 8 in order to elucidate the 
possible relationship between the inhibitory effect of our compounds and the necroptosis 
pathways.  
In our current study, we conducted the initial investigation of the possible 
mechanisms of which NBT and its metabolites exerted their inhibitory effects on 
colorectal CSCs. However, we believed that NBT and each of its metabolite should be 
studied independently in order to elucidate the mechanisms. There are multiple factors 
exist and make it hard to make the assumption that there is only one universal 
explanation for all our observation. Among all the factors, the uncertainty of the –
structure-function relationship was the most critical one that require us to be extremely 
careful and avoid over-simplifying the interpretation of certain mechanism. For example, 
it has been proposed that the elevated anti-cancer effects 5-demethylatedtangeretin (5DT) 
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was closely related to the demethylation at the 5- position in their A- ring of Tangeretin 
(TAN) [19, 267]. However, the exactly mechanism of how the structural change in the 
functional group are related to the possible change of biological activity is still unknown. 
In our case, the only structure differences between NBT and their metabolites are the 
different demethylation site at the B- ring structure. So far, there is very limited study 
have been conducted regarding such structure-functional relation (e.g. different 
demethylation site Versus different anti-cancer properties). Therefore, we suspect that for 
each compound we are studying, it could exert their functions, interacting with even 
completely different signaling pathways, based on their characterized structure.  
In conclusion, our current study for the first time demonstrated the inhibitory effects 
of NBT and its demethylated metabolites on colorectal CSCs derived from HCT116 and 
HT-29 cell line. Generally we found that compared to NBT, its metabolites were shown 
to have equivalent or even stronger effects. Our initial attempt to elucidate the 
mechanism behind such inhibitory effects indicated that apoptosis, necroptosis and 
forcing CSCs reentering cell cycle could be potential explanations for the inhibitory 
effects. We will put our future effort to further elucidation of the possible mechanism (s) 
for anti-CSC property of NBT and their metabolites, which is crucial for the overall 
assessment for their potential preventive/ therapeutic application. Most importantly, our 
previous study (unpublished) in the biotransformation of NBT and the tissue distribution 
of NBT and their metabolites in the colon mucosa provided with strong rationale to 
include the metabolites in our study; in this way, as we believe, we have made significant 
progress in evaluating the overall biological impact of NBT on colorectal cancer, 




INHIBITORY EFFECT OF 5-DEMETHYLNOBILETIN (5DN) AND ITS 
DEMETHYLATED METABOLITES ON COLORECTAL CSCS   
	  
4.1 Introduction  
Colorectal cancer is the third leading cause of death in both men and women in the 
United States. Multiple barriers obstruct the successful colorectal cancer treatment. 
Among all the challenges, tumor reoccurrence and metastasis are two major survival-
influencing factors of colorectal cancer treatment. For example, up to 40% of colorectal 
cancer patients who present with stage II or III colorectal cancer treatment will recur after 
primary treatment [1]. In colorectal cancer treatment, despite the rapid advances in 
chemotherapeutic drugs, 89% patients with metastatic disease cannot survive [2]. All 
these indicate the failure of conventional interventions including both radio- and chemo- 
therapies. Thus, it is of great important for us to develop novel and effective strategies for 
the control of colorectal cancer.  
Increasing experimental evidence begin to support that the existence of a small sup-
population of tumorigenic cells, namely, cancer stem cells (CSCs), are responsible for the 
tumor-initiation, metastasis and recurrence after conventional therapy. Multiple studies 
have suggested that the development of colorectal cancer is also CSC-dependent, which 
explains the poor prognosis and therapy failure in colorectal cancer [5, 6, 60, 115]. 
Targeting CSC compartment, therefore, become a promising solution for both the 
prevention and /or treatment of colorectal cancer [241]. 
Epidemiological and dietary interventions studies in both animal and human models 
have suggested the positive role of many dietary components in inhibiting, reversing 
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tumor development in different type of cancers [9]. So far, several of the dietary agents 
have also been shown to interfere with the function of CSCs [10]. Generally, this would 
be achievable by strategies such as inducing of differentiation, inhibiting of self-renewal 
signaling pathways and sensitizing CSC to chemotherapeutic agents [8]. For example, 
curcumin was reported to be able to impair the WNT signaling and cell-cell adhesion 
pathway in human colon cancer cell (HCT-116), which resulted in apoptosis and G2/M 
cell cycle arrest [11]. 
Polymethoxyflavones (PMFs) are a group of compounds that are almost exclusively 
found in the peels of citrus fruit [12]. So far, PMFs have been found to have wide 
spectrum of health promoting effect including anti-inflammation and anti-carcinogenesis 
[13]. Among all types of PMFs, 5-demethylated PMFs are a unique subclass, with 5-
demethylated nobiletin (5DN) as the most abundantly one that could be found in orange 
peel (especially, in aged orange peels)[18]. Even though that multiple bioactivities of 
5DN have already been studied by our group and other groups [12, 18, 19], the 
metabolites of 5DN have been scarcely investigated. Recently, our group isolated the 
metabolites of 5DN identified three novel urinary metabolites of 5DN, namely, 5,3’-
didemethylnobiletin (M1), 5,4’-didemethylnobiletin (M2), and 5,3’,4’-
tridemethylnobiletin (M3) [25]. Notably, all three metabolites have showed stronger 
inhibitory effect in human colon cancer cells  (SW480, SW620) [25].  Interestingly, 
according to our recent study (unpublished), after feeding the mice with 5DN (1000 ppm) 
for 5 months, we found an interesting tissue distribution of 5DN and its three metabolites: 
even 5DN was still the most abundant one that detected in the colon mucosa, quite a lot 
of 5DN had also been transformed into M1, M2 and M3.  Therefore, in order to fully 
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evaluate the biological impact of 5DN on colorectal cancer (or colorectal CSCs), we need 
to all the major metabolites of 5DN as well in this study. 
Herein, in this study, for the first time we investigated the inhibitory effect of 5DN 
and three of its recent identified demethylated metabolites in human colorectal CSCs.    
4.2 Materials and methods 
4.2.1 Treatment and cell culture  
HCT-116 and HT-29 Human colon cancer cell lines were obtained from American 
Type Cell Collection (ATCC, Manassas, VA, USA), and maintained in RPMI 1640 
media (Media tech) supplemented with 5% heat-inactivated fetal bovine serum and 
100U/mL of penicillin and 0.1mg/mL of streptomycin at 37°C with 5% CO2 and 95% air. 
Cells were kept subconfluent and media were changed every 3- 4 days. All cells used in 
experiments were between 4 and 20 passages. 5DN and their demethylated metabolites 
(M1, M2 and M3) were isolated and identified as previously described [25]. DMSO was 
used as vehicle to deliver 5DN and three of its metabolites to the cells. The final 
concentration of DMSO in all experiments was 0.1% v/v in cell culture media. 
The sphere culture was carried out in serum free DMEM/F12 medium (Life 
Technologies). Briefly, the serum free medium (SFM) was the supplemented with 1×B27 
(Life Technologies), 20ng/ml EGF (Life Technologies), 20ng bFGF (Life Technologies), 
5 µg/ml human insulin (Sigma-Aldrich), 100U/ml of penicillin and 0.1mg/ml of 
streptomycin.  
4.2.2 Isolation of colon cancer stem cell and tumor sphere formation assay 
Singles cells obtained from HCT-116 and HT-29 cell line were plated in ultra-low 
attachment 24-well plates (Corning, Lowell, MA, USA) at a density of 12000 viable cells 
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per well in triplicate. Cells were grown in SFM as described above at 37°C with CO2 and 
95% air. Right after seeding, cells were treated with 5DN (6.25µM, 12.5µm) and its 
demethylated metabolites (for HCT-116 M1: 0.15 µM, 0.3 µM; M2: 6.25 µM, 12.5 µM; 
M3: 6.25 µM, 12.5 µM; for HT-29  M1: 1.25 µM and 2.5µM;  M2: 6.25 µM, 12.5 µM; 
M3: 6.25 µM, 12.5 µM) for 7 days. After 7 days, tumor sphere were observed under 
microscope. For counting of spheres, cells were collected and transferred onto collagen-
coated dishes respectively and cultured in RPMI 1640 medium supplemented with 5% 
FBS. In approximately 24h, tumor sphere were adhered, then stained with crystal violet 
and counted. 
Secondary tumor sphere formation: For the passage of tumor sphere, single cells 
suspension was first obtained from primary tumor sphere by brief trypsinization. Then 
single cells from primary spheres were plated at the density of 2000 cell per well in 
triplicate. The secondary tumor spheres were grown, treated and counted as described 
above.  
In order to compare the sphere-forming potential of primary and secondary test, the 
results were further normalized as number of tumorspheres formed per 1000 seeding cells. 
4.2.3 Detection of apoptosis 
HCT-116 and HT-29 cells were seeded and treated exactly the same as described in 
cell cycle analyses above. After 7 days of incubation, apoptotic cells were quantified by 
Annexin V/propidium iodide (PI) double staining assay. Annexin V/PI staining was done 
using apoptotic detection kit (BioVision, Mountain View, CA, USA) following the 
manufacturer’s instruction. Briefly, the content of each well were collected and disrupted 
by brief trypsinization, and then washed with ice cold PBS. After another wash with 
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binding buffer, cells were suspended in 0.3 mL Annexin V binding buffer containing 
Annexin V and PI, and incubated for 5min at room temperature before analysis by flow 
cytometer. Early apoptotic cells were identified as Annexin V-positive/PI-negative cells, 
while late apoptotic/necrotic cells were identified as Annexin V-positive/PI-positive cells 
using BD LSRII cell analyzer at the analytical cytometry facility (University of 
Massachusetts Amherst). 
4.2.4 Cell cycle analyses 
HCT-116 and HT-29 cells were seeded as single cell in 6-well suspension plates in 
SFM at a density of 12000 cells per well. Right after seeding, cells were treated with 
different concentrations of NBT and demethylated metabolites. After about 7 days, the 
whole content of each well were collected by brief trypsinization (0.25% trypsin-EDTA; 
Sigma-Aldrich). Cell pellets were washed with 1mL of ice-cold PBS and then re-
suspended in 1mL of 70% ethanol in -20°C overnight. After centrifugation (1600g, 1 
min), the supernatant was removed and cells were incubated with 0.3mL of PBS 
containing 30 µg RNase (Sigma-Aldrich) and 3µg propidium iodine (Sigma-Aldrich) for 
30min at room temperature. Single-cell suspension was generated by brief trypsinization. 
Cell cycle was analyzed using a BD LSR II cell analyzer at the analytical cytometry 
facility (University of Massachusetts Amherst), and data were processed using Modifit 
LT software. 
4.2.5 Immunoblotting  
After treatment with serial concentration of 5DN and their metabolites for 7 days, 
whole cell lysate will be obtained following method as previously described [268]. 
Briefly, suspended spheroid cells will then be collected and washed with ice- cold PBS. 
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Cells will then be incubated on ice for 10 min in lysis buffer (Cell signaling, Beverly, 
MA, USA) supplemented with cocktails of protease inhibitor (1:100), phosphatase 
inhibitor I (1:100), and phosphatase inhibitor II (1:100) (Boston Bio products, Boston, 
MA, USA). After sonication (4 seconds, 4 times), cells will be incubated for 20 mins on 
ice and followed by centrifugation at 14,000 rpm using a bench top Eppendorf centrifuge 
for 20 mins at 4°C. Supernatants will be collected as whole cell lysates. Proteins will be 
quantified by BCATM protein assay kit (Pierce Biotechnology, Rockford, IL, USA), and 
50-150 µg of proteins will be resolved either by 8%, 12% or 15% SDS-polyacrylamide 
gel electrophoresis and then transferred to nitrocellulose membrane. The membrane 
containing the transferred protein will be blocked in blocking buffer (5% nonfat dry milk, 
1% Tween-20 in 20 mM Tris-buffered saline, pH 7.4) for 2 h at room temperature, and 
then incubated with appropriate primary antibodies in blocking buffer overnight at 4°C. 
After incubation with appropriate secondary antibodies for 2 h at room temperature, the 
membranes will be washed with Tris buffer containing 0.5% of Tween-20, and then be 
visualized using enhanced chemiluminescence kit (Boston Bio products, Ashland, MA, 
USA). Antibodies for p21Cip1/Waf1, p53, RIP3, poly ADP ribose polymerase (PARP) and 
cyclin D1 will be obtained from Cell Signaling Technology (Beverly, MA, USA). β-
Actin (Sigma-Aldrich) will be used as a loading control. 
4.2.6 Statistical analysis  
All data were presented as mean	  ± SD. Student’s t-test was used to determine the 
mean difference between two groups. Analyses of variance (ANOVA) model was used 
for the comparing the differences among more than two groups. A1% significant level 





4.3.1 5DN and its demethylated metabolites inhibited tumor-sphere formation in 
colorectal CSCs 
To determine whether the treatment of 5DN and their demethylated metabolites 
would influence the proliferation of colorectal CSCs, we conducted tumor sphere 
formation assay on spheroid cells derived from both HCT-116 and HT-29 cell lines 
(Figure.19 and Figure. 20). Specifically, HCT-116 and HT-29 cells were seeded as single 
cell in Serum-free medium (SFM) and treated with NBT (6.25µM- 12.5µM) or three 
demethylated metabolites: M1 (0.15µM-0.3µM), M2 (6.25µM-12.5µM) and M3 
(6.25µM-12.5µM). The tumor sphere-forming potential of both primary and secondary 
CSCs were analyzed. For CSCs derived from HCT-116 cell line (Figure 19 A and B), the 
primary tumorsphere forming frequency in the control group got increase from about 0.4% 
(4 tumorspheres formed per 1000 seeding cells) to about 1.7% (17 tumorspheres formed 
per 1000 seeding cells) in the secondary test, this further supported the notion that 
sphere-culturing in SFM as an effective tool in enriching the CSC subpopulation. 
Compared to the control group, the sphere-forming ability following each treatment was 
significantly impaired in a nearly dose-dependent manner. As shown in Figure 19 the 
treatment of 5DN at 6.25µM resulted in a nearly 65% percent of inhibition of primary 
tumorsphere, and at 12.5µM, the inhibitory effect got increased to almost 100%. Then we 
compared the inhibitory effect of three of its demethylated metabolites (M1, M2 and M3) 
with that of 5DN (Figure 19 A): for both primary and secondary tumorsphere formation 
test, the treatment of 5DN (12.5µM) showed stronger inhibitory effects compared to the 
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two of metabolites, M2 (12.5µM) and M3 (12.5µM); For example, while 5DN (12.5µM) 
led to a 100% inhibition in secondary tumor sphere formation, M2 (12.5µM) only 
resulted in a 75% reduction. Among all the demethylated metabolites, M1 showed to 
have the strongest effect (Figure19 B). For example, in both primary and secondary 
tumorsphere formation test, M1 at the dose as low as 0.15µM, showed almost the same 
inhibitory effect as that exerted by 5DN at 6.25µM, which indicated that the M1 was 
more than 40 times potency than 5DN.  Plus, such inhibition of sphere-forming potential 
was also observed as the reduction of both the numbers and the sizes of tumorspheres 
(Figure 19 C). 
Similar pattern was also observed in the tumorsphere-forming ability of CSCs 
derived from HT-29 cell line compared to the control group, the treatment of 5DN and its 
demethylated metabolites (M1, M2 and M3) resulted in a significant decrease in the 
sphere-forming potential in both primary and secondary test (Figure 20 A and B). For 
example, M2 (12.5µM) resulted in the inhibition of tumorsphere formation by 67% and 
82% in primary and secondary test, respectively. Then we compared the effect of three 
demethylated metabolites (M1, M2 and M3) with that of 5DN: as shown in Figure 20 A, 
for both primary and secondary test, at the dose of 12.5µM, 5DN showed significantly 
stronger inhibitory effect than those groups treated with M2 (12.5µM) or M3 (12.5µM). 
Among all the demethylated metabolites of 5DN, M1 showed the highest potency (Figure 
20 B). For example, in the primary test, M1 at the does as low as 1.25µM, led to almost 
80% inhibition in tumorsphere formation, while 5DN at 12.5µM only resulted in 68% 
inhibition. Plus, such inhibitory effects were also observed in the reduction of both the 
numbers and sizes of tumorspheres (Figure 20 C).   
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Overall, we found that the effects of metabolites were comparable to that of 5DN. 
	  
Figure 19.	  The treatment of 5DN and its demethylated metabolites (M1, M2 and M3) 
inhibit the tumorsphere formation of colorectal CSCs derived from HCT-116 cell line.  
(A) and (B)  For the primary tumorsphere formation assay, single cells from HCT-116 
cell line were seeded in 24-well ultra-low attachment plates (12000 cells per well); for the 
secondary tumorsphere formation, single cells obtained from the primary tumorspheres as 
described in Material and Methods were seeded in 24-well ultra-low attachment plates 
(2000 cells per well,) in triplicate in a serum-free (SFM) medium. Right after seeding, 
CSCs were treated with 5DN (6.25µM to 12.5µM) and three of its demethylated 
metabolites: M1 (0.15µM to 0.3µM), N2 and N3 (6.25µM to 12.5µM). After 7 days, 
primary/ secondary tumorspheres were collected and counted. All data represent mean ± 
SD, * indicated the statistical significance of each treatment in comparison with the 
control (DMSO) group, as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical 
significance of metabolites-treating groups in comparison with the 5DN-treating group, 
as #p<0.05, ##p<0.01, ###p<0.001. (C) Tumorsphere culture demonstrating sphere-
formation of colorectal CSCs derived from HCT-116 cell line following the treatment 





Figure 20.	  The treatment of 5DN and its demethylated metabolites (M1, M2 and M3) 
inhibit the tumorsphere formation of colorectal CSCs derived from HT-29 cell line.  
(A) and (B)  For the primary tumorsphere formation assay, single cells from HT-29 cell 
line were seeded in 24-well ultra-low attachment plates (12000 cells per well); for the 
secondary tumorsphere formation, single cells obtained from the primary tumorspheres as 
described in Material and Methods were seeded in 24-well ultra-low attachment plates 
(2000 cells per well,) in triplicate in a serum-free (SFM) medium. Right after seeding, 
CSCs were treated with 5DN (6.25µM to 12.5µM) and three of its demethylated 
metabolites: M1 (1.25µM to 2.5µM), N2 and N3 (6.25µM to 12.5µM). After 7 days, 
primary/ secondary tumorspheres were collected and counted. All data represent mean ± 
SD, * indicated the statistical significance of each treatment in comparison with the 
control (DMSO) group, as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical 
significance of metabolites-treating groups in comparison with the 5DN-treating group, 
as #p<0.05, ##p<0.01, ###p<0.001.  (C) Tumorsphere culture demonstrating sphere-
formation of colorectal CSCs derived from HT-29 cell line following the treatment with 




4.3.2 5DN and its demethylated metabolites induced apoptosis (necroptosis) in 
colorectal CSCs. 
We next examined the extent to which cell death pathways such as apoptosis and/or 
necroptosis contributed to the inhibitory effect of 5DN and its demethylated metabolites 
on tumorsphere forming capacity of CSCs as we have demonstrated in Chapter 4.3.1. For 
CSCs derived from HCT-116 cell line (Figure. 21), all the treatments including 5DN 
(12.5µM), M1 (0.3µM), M2 (12.5µM) and M3 (12.5µM) significantly induced apoptosis 
(necroptosis) compared to the control group. As shown in Figure 21 A, 5DN (12.5µM) 
resulted in a 2.5 -fold increase (from 5.5% to 13.9%) in the late phase apoptotic (or 
necroptotic) population compared to the control group. Notably, M3 (12.5µM) increased 
the total apoptotic (or necroptotic) population by 5-fold, compared to the control group 
(from 6.7% to 30.7%). Among all the metabolites of 5DN, M1 was the most potent one 
(Figure 21 B). For example, the treatment of M1 at the concentration as low as 0.3µM 
resulted in the total apoptotic population as 24%, while 5DN (12.5µM) only resulted in 
the total apoptotic (or necroptotic) population of 16%.  
Similar pattern were also observed in the CSCs derived from HT-29 cell line (Figure  
22 ). Particularly, compared to the control group, all treatments led to signify of induction 
of apoptotic (necroptotic) cells. As shown in Figure 22 A, 5DN (12.5µM) increased the 
total apoptotic (necroptotic) cells population from 4.4% to 13.7%; then we compared the 
apoptosis (necroptosis) inducing ability of 5DN (12.5µM) with those of M2 (12.5µM) 
and M3 (12.5µM). The results showed that 5DN(12.5µM) induced more apoptotic 
(necroptotic) cell population than M2 (12.5µM); no significant difference was observed 
between 5DN(12.5µM) and M3 (12.5µM).  As shown in Figure  22 B, M1 (1.25µM) 
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induced nearly 10% of total apoptotic (or necroptotic) cell population; even though 5DN 
(12.5µM) induced more apoptosis cells than M1, when considering that the concentration 
for M1 was 10-time less than that of 5DN, it might still indicate that M1 was much more 
potent than 5DN.   
Overall, we found that the effects of metabolites were comparable with that of the 
parent compound, 5DN. Especially, we found that M1 was the most potent one among all 




Figure 21.	  The treatment of 5DN and its demethylated metabolites induced apoptosis (or 
necroptosis) in CSCs derived from HCT-116 cell line. (A) and (B) HCT-116 cells were 
seeded as single cell in 6-well suspension plates in SFM at a density of 12000 cells per 
well. Right after seeding, cells were treated with 5DN (12.5µM) and demethylated 
metabolites M1(0.3µM), M2(12.5µM)  and M3 (12.5µM). After 7 days, apoptotic cells 
were quantified by Annexin V/propidium iodide (PI) double staining assay as described 
in Materials and Methods. FITC high/ PI low cells were defined as early apoptotic cells, 
FITC high/ PI high cells were defined as late apoptotic (or necroptotic) cells. All data 
represent mean ± SD, * indicated the statistical significance of each treatment in 
comparison with the control (DMSO) group, as *p<0.05, **p<0.01, ***p<0.001; # 
indicated the statistical significance of metabolites-treating groups in comparison with the 
5DN-treating group, as #p<0.05, ##p<0.01, ###p<0.001.  (C) The distribution pattern of 





Figure 22.	  The treatment of 5DN and its demethylated metabolites induced apoptosis (or 
necroptosis) in CSCs derived from HT-29 cell line. (A) and (B) HT-29 cells were seeded 
as single cell in 6-well suspension plates in SFM at a density of 12000 cells per well. 
Right after seeding, cells were treated with 5DN (12.5µM) and demethylated metabolites 
M1(1.25µM), M2(12.5µM)  and M3 (12.5µM). After 7 days, apoptotic cells were 
quantified by Annexin V/propidium iodide (PI) double staining assay as described in 
Materials and Methods. FITC high/ PI low cells were defined as early apoptotic cells, FITC 
high/ PI high cells were defined as late apoptotic (or necroptotic) cells. All data represent 
mean ± SD, * indicated the statistical significance of each treatment in comparison with 
the control (DMSO) group, as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical 
significance of metabolites-treating groups in comparison with the 5DN-treating group, 
as #p<0.05, ##p<0.01, ###p<0.001. (C) The distribution pattern of CSCs (HCT-116) 




4.3.3 5DN and its demethylated metabolites caused cell-cycle redistribution in 
colorectal colon cancer cells 
We next investigate the possible effects of 5DN and its demethylated metabolites on 
the cell cycle distribution of CSCs. Theoretically, the quiescence (or slow cycling) nature 
of CSCs would make most of CSCs stay in the G0/G1 phase [122] .  
For CSCs derived from HCT-116 cells (Figure 23), about 80% of cells in the control 
group were found in the G1/G0 phase. Plus, All the treatment decreased the cell 
distribution in G1/G0 phase compared to the control group. For example, the treatment of 
M3 (12.5µM) decreased the cells distribution in G1/G0 phase from 80% to 74%; Then 
we compared the effect of three metabolites with that of 5DN. As shown in Figure 23 A  
and B, compared to M1 (0.3µM), M2 (12.5µM) and M3 (12.5µM), the treatment of 5DN 
(12.5µM) showed stronger capacity in reducing the cell population in G1/G0 Phase.  
Similar pattern was also observed in CSCs derived from HT-29 cell line (Figure 24). 
The treatment of 5DN (12.5µM), M1 (1.25µM), M2 (12.5µM) and M3 (12.5µM) all 
decreased the cell cycle population in G0/G1 phase.  
Generally, the effects of metabolites were comparable with that of 5DN, with M1 






Figure 23. The treatment of 5DN and its demethylated metabolites altered the Cell Cycle 
distribution of CSCs derived from HCT-116 cell line. (A) and (B) HCT-116 cells were 
seeded as single cell in 6-well suspension plates in SFM at a density of 12000 cells per 
well. Right after seeding, cells were treated with 5DN (12.5µM) and demethylated 
metabolites M1 (0.3µM), M2 (12.5µM) and M3 (12.5µM). After 5 day, cells were 
collected and subjected to cell cycle analyses as described in Material and Methods. All 
data represent mean ± SD, * indicated the statistical significance of each treatment in 
comparison with the control (DMSO) group as *p<0.05, **p<0.01, ***p<0.001; # 
indicated the statistical significance of metabolites-treating groups in comparison with the 
NBT-treating group, as  #p<0.05, ##p<0.01, ###p<0.001. (B) Cell cycle distribution of 







Figure 24. The treatment of 5DN and its demethylated metabolites altered the Cell Cycle 
distribution of CSCs derived from HT-29 cell line. (A) and (B) HT-29 cells were seeded 
as single cell in 6-well suspension plates in SFM at a density of 12000 cells per well. 
Right after seeding, cells were treated with 5DN (12.5µM) and demethylated metabolites 
M1 (1.25µM), M2 (12.5µM) and M3 (12.5µM). After 5 day, cells were collected and 
subjected to cell cycle analyses as described in Material and Methods. All data represent 
mean ± SD, * indicated the statistical significance of each treatment in comparison with 
the control (DMSO) group as *p<0.05, **p<0.01, ***p<0.001; # indicated the statistical 
significance of metabolites-treating groups in comparison with the NBT-treating group, 
as  #p<0.05, ##p<0.01, ###p<0.001. (B) Cell cycle distribution of CSCs (HT-29) 






4.3.4 5DN and its demethylated metabolites inhibited the growth of colorectal CSCs 
by regulating key proteins related to apoptosis, necroptosis and cell cycle.  
In order to elucidate the molecular mechanisms governing the inhibitory effects of 
5DN and its demethylated metabolites (M1, M2 and M3) on CSCs from both HCT-116 
and HT-29 cell line, we analyzed the effects of treatments on some key proteins in 
regulating cell cycle and apoptosis by immunoblotting analysis as described in chapter 
3.2.5.  
To confirm the apoptosis-inducing effect of our treatment, we examined their effects 
on poly ADP ribose polymerase (PARP) and p53 (for possible p53-dependent apoptosis). 
In Figure 25, we compared the effects of M2 and M3 with that of 5DN. According to the 
results, for CSCs derived from HCT-116, 5DN and all its metabolites increased the level 
of p53; plus, all of our treatments resulted in increased the expression of cleaved PARP, 
which is the indicator of apoptosis. For CSCs derived from HT-29, it was found that both 
the level of p53 and cleaved PARP got increased following our treatment. In Figure 26, 
we compared the effects of M1 and 5DN. According to the results, both 5DN and M1 
resulted in the increased expression of p53 and cleaved-PARP, which could be used to 
support our observation in the apoptosis detection. 
 In cell cycle arrest, p21 is transcriptionally regulated by p53. Plus, p21 has also 
been found to control entry into quiescence and maintaining of the quiescent state [282]. 
According to our result (Figure.25 and Fig. 26), in CSCs derived from HCT-116, there 
was a significant increase in the level of p21 followed by the treatment of 5DN (12.5µM), 
M2 (12.5µM) and M3(12.5µM); however, an opposite trend was found following the 
treatment of M1 (0.3µM), where the level of p21 get dramatically decreased. As for CSCs 
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derived from HT-29, the level of p21 got decreased after the treatments of 5DN(µM) and 
M2 (12.5µM), while M1 (1.25µM) and M3 (12.5µM) led to the increased level of p21. 
Cyclin D1 Plays a central role in the entry of cell cycle from G0/G1 phase, especially, in 
the G1/S transition [283]. According to our results (Figure 25 and 26), all the treatments 
led to the increased expression of cyclin D1 in CSCs derived from both cell lines. 	  
	  
Figure 25. Effects of 5DN and its demethylated metabolites (M2 and M3) in modulating 
key proteins regulating apoptosis and cell cycle. Immunoblots displayed the treatment of 
NBT (12.5µM) and three of its metabolites: M2 (12.5µM), M3 (12.5µM) on p21cip1/Waf1, 
p53, cleaved PARP and cyclin D1 on CSCs derived from HCT-116 and HT-29. The 
numbers under the blots represent band intensity (normalized to β-actin, means of three 
independent experiments). The standard deviations (all within ± 15% of the means) were 








Figure 26. 	  Effects of 5DN and its demethylated metabolites M1 in modulating key 
proteins regulating apoptosis and cell cycle. Immunoblots displayed the treatment of M1 
(0.3µM for HCT-116 and 1.25µM for HT-29) on p21cip1/Waf1, p53, cleaved PARP and 
cyclin D1 on CSCs derived from HCT-116 and HT-29. The numbers under the blots 
represent band intensity (normalized to β-actin, means of three independent experiments). 
The standard deviations (all within ± 15% of the means) were not shown. β-actin served 
as an equal loading control. 
	  
	  
  Besides apoptosis, necroptosis is also regarded as an important programmed 
pathway way, especially when apoptosis fails for multiple reasons. Therefore, in our 
study, we also test that whether our treatments could result in the level change of the 
RIP3, one of the markers of the necroptosis pathway. As shown in Figure 27, for CSCs 
derived from HCT-116, all the treatments increased the expression of RIP3; while for 







Figure 27. Effects of 5DN and its demethylated metabolites (M1, M2 and M3) in 
modulating one of key molecular marker of necroptosis, RIP3. Immunoblots displayed 
the treatment of 5DN (12.5µM), M1 (0.3µM for HCT-116 and 1.25µM for HT-29), M3 
(12.5µM) and M3 (12.5µM) on the protein expression of RIP3 in CSCs derived from 
HCT-116 and HT-29. The numbers under the blots represent band intensity (normalized 
to β-actin, means of three independent experiments). The standard deviations (all within 
± 15% of the means) were not shown.β-actin served as an equal loading control. 
4.4 Discussion 
Among all types of PMFs, 5-demethylated PMFs are a unique subclass, with 5-
demethylated nobiletin (5DN) as the most abundantly one that could be found in orange 
peel (especially, in aged orange peels) [18]. The bioactivities of 5DN have already been 
studied by our group and other groups [12, 18, 19]. In order to understand the overall 
function of certain bioactive compound, we also need to take the biotransformation into 
account. So far, the metabolites of 5DN have been scarcely investigated. Recently, our 
group isolated and identified 3 novel urinary metabolites of 5DN, namely, 5,3’-
didemethylnobiletin (M1), 5,4’-didemethylnobiletin (M2), and 5,3’,4’-
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tridemethylnobiletin (M3) [25]. Notably, all three metabolites have shown stronger 
inhibitory effect in human colon cancer cells  (SW480, SW620) [25]. However, all these 
studies mentioned above were only focused on their effects on the bulk of cancer cells, no 
reports has yet been published on possible effects of 5DN and its metabolites targeting 
the CSCs. 
 In vitro tumor sphere formation has already been proved to be an effective tool in 
the study of CSCs [85]. In our research, we determined the effects of 5DN and their 
metabolites in both primary and secondary tumor formation. According to our results, it 
was found that the frequency of sphere-forming cells in the secondary culture was almost 
3 folds as high as that in the primary culture, which further confirmed the “CSCs-
enriching” function of the suspension sphere culture. There are evidence supporting that 
such spheroid- forming cells has significant higher “tumor-initiating” ability in the 
transgenic mouse model than cells cultured with conventional methods [84, 91, 92]. 
Since we have found in our previous study in the study of bulk cancer that M1, one of the 
major metabolites of 5DN, showed significantly potency compared to 5DN and 
metabolites, thus in this study, the effects of M1 will be separated from other two 
metabolites and then compared with the effects of 5DN.  According to the result from the 
tumorsphere formation study, we found that for both CSCs derived from HCT-116 and 
HT-29 cell line, the treatment of 5DN or their demethylated metabolites could 
significantly impair the in vitro sphere-forming ability. Notably, M1 at much lower 
concentration, showed nearly the same level of effects compared to both 5DN and other 
metabolites. For example, according to our results, it was shown that M1 was 40 and 10 
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times as potency as the parent compound 5DN, in treating CSCs from HCT-116 and HT-
29, respectively. 
Furthermore, prolonged treatment of 5DN or their metabolites resulted in the 
induction of apoptotic cells as well as a shift in the cell cycle redistribution in CSCs 
derived from both cell lines. Interestingly, we have observed that for each cell line, the 
level of responses differs when cells were subjected to different treatment (5DN or 
metabolites), generally, it was observed that the effects of metabolites were comparable 
with those of the parent compound, 5DN; particularly, we have found that M1 exerts the 
strongest effects among all the metabolites as well 5DN.  On the hand, results also 
showed that CSCs derived from the two cell line, responded differently when subjected to 
the same treatment. This may indicate that the phenotype difference may contribute to the 
different cellular- sensitivity.  
So far, with several research have been focused on the regulation of self-renewal, 
proliferation and differentiation of CSCs, studies of cell death pathways including 
apoptosis and necroptosis are still quite limited [168]. In this study, we examined whether 
5DN and their demethylated metabolites exert the inhibitory effect on CSCs by regulating 
some of the key modulators in apoptosis, necroptosis, cell cycle distribution (re-entering 
the cell cycle). 
The cleavage of PARP facilitates cellular disassembly and serves as a marker of 
cells undergoing apoptosis [284]. Our results in immunoblotting showed that within each 
cell line we have test, the treatment of NBT or metabolites resulted in the increased level 
of cleaved -PARP compared to the control group. For example, M3 (12.5µM) resulted in 
more 10-fold increase in the level of the cleaved -PARP compared to the control group. 
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Such increases in cleaved PARP were in line with our observation in the apoptosis test by 
flow cytometry. 
The tumor suppressor, p53, has been implicated in a variety of cellular processes 
and regarded as the “guardian of the genome’’ in cells. It exerts its function by inducing 
apoptosis and growth arrest. According to our results, treatment of NBT and metabolites 
resulted in the up-regulation of p53 in CSCs derived from HCT-116, especially 
significant after the treatment of 5DN (12.5µM), M1 (0.3µM) and M2 (12.5µM). This 
may indicate that the inhibitory effect of our treatment was p53 -dependent in CSCs 
derived from HCT-116 cell line. On the hand, for CSCs derived from HT-29 cell line, the 
level of total p53 protein only got slightly increased following our treatment. A possible 
explanation would be that rather than an elevation in the total p53 level; the treatment 
could lead to the more significant increase in the serine phosphorylation level of p53. In a 
study using curcumin to treat HT-29 cells, high level of the serine phosphorylation of p53 
(while total p53 remains unchanged) was shown to be able to down-regulate the anti-
apoptotic factor, Bcl-2 and up-regulating the pro-apoptotic factor Bax, thereby decreasing 
the Bcl-2/Bax ratio and disposing to apoptosis [285].  
Recently, the role of p53 in cancer stem cell has been discussed in detail by Aloni-
Grinstein et al.[286]. Particular, it has been proposed that p53 can also function as a 
differentiation inducer in various cell types, which place it as an attractive candidate for 
differentiation therapy in control of CSCs [286]. According to our result in this study, 
increased level p53 was observed in CSCs derived from HT-116 and HT-29. Though 
evidence is still vastly lacked, this might also be novel for our understanding of the 
mechanism behind the inhibitory effect of NBT and metabolites on colorectal CSCs. 
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The CDK inhibitor  p21CIP1/ WAF1, is a member of Cip/Kip family and responsible for 
both p53 dependent and p53-independent cell cycle arrest [287]. During the p53- 
dependent cell cycle arrest, p21 served as a down stream transcriptional targets of p53; 
increased levels of p53 would also result in increased level of p21CIP1/ WAF1, which will in 
turn contributes to cell cycle arrest. As for our study, such pattern (increased p21CIP1/ WAF1, 
plus increased p53 protein level) was observed in CSCs derived from HCT-116 followed 
by the treatment of 5DN (12.5µM), M2 (12.5µM) and M3 (12.5µM). A similar trend was 
also found in HT-29 derived CSCs after the treatment M1 (1.25µM). This could indicate 
that above mentioned treatments might probably exert their function through p53- 
dependent p21 mediated pathway.  
Evidence supported that disruption of cell cycle inhibition may also contribute to the 
very nature of CSCs, especially in breaking the balance between the self-renewal and 
differentiation, which lead to the deregulated self-renewal of CSCs [203]. Theoretically, 
the quiescence (or slow cycling) nature would make most of CSCs stay in the G0/G1 
phase. As has been discussed in chapter 2.3.2, quiescence is one of the major mechanisms 
contributing the therapy resistance of CSCs. Particularly, G0 phase is viewed as either an 
extended G1 phase, where the cell is neither dividing nor preparing to divide, or a distinct 
quiescent stage that occurs outside of the cell cycle [122]. It has also been proposed that, 
targeting p21 or its down stream target may be an effective means to force quiescent 
CSCs to cell cycle and thereby cells will be more susceptible to chemotherapies and 
undergo apoptosis.  As for our cell cycle analysis, we found that for control group from 
each cell line, 70% to 80% of total population of CSCs was in the G0/G1 phase, which is 
not usual in our study of the bulk of cancer cells (data not shown). This could be an 
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indication that majority of cells in the suspension culture are CSCs. According to our 
observation in the cell cycle detection and immunoblotting, a decrease in G0/ G1 phase 
cell population for both cell lines; In addition, reduced levels of p21 was found in HCT-
116 after the treatment of M1 (0.3µM) and in HT-29 after treatment of 5DN (12.5µM), 
M2 (12.5). Cyclin D1 plays a central role in the entry of cell-cycle, particularly, high 
level of cyclin D1 expression can be an indicator G1/S transition [283]. According to our 
results, in CSCs derived from both HCT-116 and HT-29 cell line, all our treatments 
(NBT and metabolites) led to increased expression cyclin D1, which were in line with our 
observation in the cell cycle distribution (CSCs re-entered the cell cycle).  Still, further 
evidence is needed to connect the inhibition of above-mentioned treatments on CSCs and 
the possible inducing of CSCs to  “re-enter” the cell cycle.  
Besides apoptosis, evidence has been accumulated supporting that apoptosis is not 
the only mechanisms that could control the cell death. Specifically, necroptosis, also 
known as the programmed necrosis, has gained more attention in recent years. Besides 
the necrosis-like morphology changes, necroptosis are also believed to maintains part of 
the apoptotic features as apoptosis [188, 189]. In our research, we also hypothesize that 
necroptosis could be another factor contributed to the inhibitory effects of 5DN and 
metabolites on colorectal CSCs. Specifically, our hypothesis was based on the following 
reasons: 1. Possible limitation exists for our methods in “apoptotic” cell detection. Time-
lapse imaging, which allows monitoring of morphological changes in individual cells in a 
dynamic and comparative manner, is so far the most effect way to reveal the differences 
between apoptosis and necrosis (necroptosis) [288]. However, during our research, cells 
were analyzed by flow fluorocytometry for exposure of phosphatidylserine (PS, 
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characterized by the binding of FITC) and changes in permeability (uptake of propidium 
iodide, characterized by binding of PI). Notably, in apoptosis, membrane changes will 
lead to a rapid PS exposure, while the permeability change will be lagged behind [288] . 
Such phenomena result in the steady shift from early phase apoptosis (PI low / FITC high 
cells) to late phase apoptosis (PI high / FITC high cells); for necroptosis (necrosis), PS 
exposure overlaps with the changes with permeability changes, which result in the rapid 
shift of cell population from lower left corner (PI low / FITC low cells) to the upper right 
corner (PI high / FITC high cells). Therefore, in our research, since we only tested the cell 
distribution pattern at the end of 7- day incubation, the upper right cells preciously 
defined as “late phase apoptosis” cells, could also be cells went through “necrosis 
(necroptosis)”; 2. It has been reported that necroptosis is an alternative cell death pathway 
especially when apoptosis cannot be achieved because of the ATP failure (apoptosis is 
the most energy-consuming process since that it requires the activation of multiple 
caspases and the formation of apoptosome) [200-202]. As in our study, CSCs were 
derived in serum free medium (SFM) supplemented with growth factors (see Material 
and Methods) and cultured extensively for 7 days. Such condition would result in the 
possible “energy starvation” thus necroptosis could be accounted as an alternative death 
pathway involved. 3. One of the key characters of CSC is higher apoptosis-resistance 
compared to the non-CSC counterpart [289], this could be another reason besides ATP 
failure that can make necroptosis an alternative explanation for the inhibitory effect of 
our treatment.  
To test hypothesis, we test the expression of the RIP3, one of the key molecular 
regulators of necroptosis [192, 193] by immunoblotting. It was shown that our treatment 
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caused increased RIP3 level in CSCs derived from HCT-116, with M1 (0.3µM)  and M3 
(12.5µM) having the strongest effect. While for CSCs derived from HT-29, only the 
treatment of M1 (1.25µM) showed RIP increasing potential. Evidence have been 
supporting that caspase 8 plays opposite roles in cross-talk between apoptosis and 
necroptosis: TNF activate apoptosis by triggering a series of molecular events which 
eventually lead to the activation of caspase 8; while in necroptotic pathway, the function 
of caspase 8 is disrupted or even inhibited [191]. Therefore, we will further confirm our 
observation by assessing the level of caspase 8 in order to elucidate the possible 
relationship between the inhibitory effect of our compounds and the necroptosis 
pathways.  
In our current study, we conducted the initial investigation of the possible 
mechanisms of which 5DN and its metabolites exerted their inhibitory effects on 
colorectal CSCs. However, we believed that 5DN and each of its metabolite should be 
studied independently in order to elucidate the mechanisms. There are multiple factors 
exist and make it hard to make the assumption that there is only one universal 
explanation for all our observation. Among all the factors, the uncertainty of the –
structure-function relationship was the most critical one that require us to be extremely 
careful and avoid over-simplifying the interpretation of certain mechanism. For example, 
it has been proposed that the elevated anti-cancer effects 5-demethylatedtangeretin (5DT) 
was closely related to the demethylation at the 5- position in their A- ring of Tangeretin 
(TAN) [19, 267]. However, the exactly mechanism of how the structural change in the 
functional group are related to the possible change of biological activity is still unknown. 
In our case, the only structure differences between 5DN and their metabolites are the 
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different demethylation site at the B- ring structure. So far, there is very limited study 
have been conducted regarding such structure-functional relation (e.g. different 
demethylation site Versus different anti-cancer properties). Therefore, we suspect that 
each compound we are studying could exert their functions by interacting with 
completely different signaling pathways, based on their characterized structure.  
In conclusion, our current study for the first time demonstrated the inhibitory effects 
of 5DN and its demethylated metabolites on colorectal CSCs derived from HCT116 and 
HT-29 cell line. Generally, we have found that the effects of metabolites were 
comparable to those of 5DN, with M1 having the strongest effects among all our 
treatments. Our initial attempt to decipher the mechanism behind such inhibitory effects 
indicated that apoptosis, cell cycle pathways, necroptosis as well as the “quiescence” 
nature of CSCs could be potential targets of our compounds of interests. We will put our 
future effort to further elucidation of the possible mechanism (s) for anti-CSC property of 
5DN and their metabolites, which is crucial for the overall assessment for their potential 
preventive/ therapeutic application. Most importantly, our previous study (unpublished) 
in the biotransformation of 5DN and the tissue distribution of 5DN as well as their 
metabolites in the colon mucosa provided with strong rationale to include the metabolites 
in our study; in this way, as we believe, we have made significant progress in evaluating 







GENERAL DISCUSSION AND THE ROAD AHEAD  
 
5.1 Challenges in the cancer stem cell study  
Though regarded as one of the hottest topic in the research of cancer, the field of 
CSC-study it still at the nascent stage; as a result, multiple challenges exist with the field.  
One of the most debated areas is the isolation and quantification of CSCs. As we 
have discussed in previous chapters, the use of surface of markers, xenograft in murine 
model and in vitro spheroid cultures have been the major tools used to study the 
colorectal CSCs. The use of surface makers, as many researchers believes may not be the 
optimal method to purify CSCs from the tumor bulk. One argument is that the significant 
amount of genetic variability exist in the colorectal caner may not necessarily be reflected 
as change in the phenotype [44]. For example, due to the absence of mRNA 
downregulation after colorectal CSC differentiation, CD133, generally regarded as “solid” 
marker, has been criticized recently [290]. In a study of lung CSCs, it was shown that the 
cell surface marker differs among tumors initiated by oncogenic K-ras, EGFR, suggesting 
that the genotype of the tumor must be identified for the proper characterization of the 
CSCs， in other world, the use of CSC surface markers should be carefully defined for 
each tissue and tumor sub-type.  
The xenograft assay, though regarded as the “golden standard” in the preclinical 
CSC research, is still facing criticisms. One of the major concerns is that since xenograft 
is basically identifying CSC fraction in transgenic murine model, the microenvironment 
of the mouse might have completely different impact on CSC behavior relative to that of 
human. Plus, evidence has shown that the CSC frequency varies among different 
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transgenic models used [291]. Given the clinical relevance of both the frequency and 
properties of CSCs, it is of great important to choose the best available xenograft model 
for every individual tumor subtype.  
The spheroid culture has been seen as the most convenient tool in isolating and 
expanding colorectal CSCs [6, 92, 103]. Utilizing such tool, a large number of CSCs can 
be prepared for multiple experimental purposes such as in vivo xenografts. However, 
some scientists have criticized the use of convention cell lines as the source of the 
spheroid culturing. The multiple passages that cell lines undergo in the in vitro setting 
may result in huge behavioral change compared to the cells in human patients. Rather, it 
has been suggested that using primary samples from human patients may render a better 
credibility.   
The other challenge in the study of CSC has been to answer the question the whether 
the CSCs are static or plastic.  It has been found that normal stem cells can re-enter the 
stem cell [292], this shed light on the idea that is could also be possible that CSCs can be 
generated from non-CSCs under certain situation [293]. Such reversibility of 
tumorigenicity has been supported by some studies using in vitro models [294, 295]. 
Besides, the microenvironment, which CSCs reside, might be able to induce the 
“stemness” in non-CSC component. For example, in an intestinal tumor initiation mouse 
model, epithelial non-CSC can reexpress stem cell markers followed by Wnt activation, 
and thereby “dedifferentiate” to CSCs [296]. A better understanding of the possible 





5.2 Friend or Foe: the multiple roles of intestinal microbiota in the cancer 
development and diet-based chemoprevention.  
Traditionally, our perception of the function of the large intestine has been limited to 
the reabsorption of water, salt as well as removing of the “useless” food debris; such 
understanding almost completely ignores the presence of the microbiota. The fact is, in 
human body, more than 100 trillion microbiota are found in the intestines, which are 
necessary for the maintenance of physiologic homeostasis. Notably, significant 
variability exists in terms of the density as well as the complexity of the microbiota: for 
example, the gut flora consists of 300 to 1000 different species of bacteria, which exert 
multiple metabolic activities [297]. Evidence have shown that gut microbiota have about 
100 times more genes compared to those in human genome [298]. In recent years, 
advances in technology such as sequencing has fueled the microbiota research, especially, 
it has been widely accepted that microbiota can be seen as the “forgotten” organ [299]. 
Interestingly, it has been proposed that the higher microbial density in the colorectal 
compared to that in small intestine, may contribute to the much higher incidence of 
cancer in the colorectal relative to the small intestine [300].  
As has been discussed in chapter 2.2.4, the tumor microenvironment has been 
recognized as one of the “hallmarks” epithelial cancers including colorectal cancer. As 
one of the key compartment of the microenvironment, microbiota also contribute to the 
carcinogenesis. According to studies in germ-free animals, a number of microbiota 
species are able to initiate and promote intestinal tumorigenesis [301, 302]. So far, it is 
still unknown that whether such tumor-promoting effects of the microbiota are due to one 
particular species or whether a small community of species is responsible [303]. Even 
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though that there is so far very limited reports concerning the implication of microbiota 
on the development of colorectal cancer under the CSC hypothesis; however, the future 
study of the host-microbiota interaction may shed light on the understanding of the CSC 
biology. 
Besides the tumor-promoting potential of certain specifies within the intestinal 
microbiota, there might also be some species that are playing important, if not central 
roles in the metabolism of bioactive compound found in the food matrix. Generally, with 
so many efforts have been put in search of the diet-base chemopreventive strategies, our 
understanding of the possible influence of diet on cancer occurrence is still poorly 
characterized [28]; this may at least partial due to our previous ignorance of the 
microbiota in the large intestine. Studies begin to accumulating showing that while in 
most cases, bacterial metabolism reduces the activity of dietary compounds; however, 
sometimes a specific product of bacterial transformation exhibits enhanced or more 
beneficial properties [304]. In other words, the bioactive properties of metabolites can be 
completely different from the parent compounds. For example, while the majority of 
dietary anthocyanins cannot be absorbed in the upper gastrointestinal tract, they would 
therefore be further metabolized by intestinal microbiota and become “absorbable” in the 
colon; such transformation may render anthocyanins with stronger impact on the 
microbiota as well as the host [305].  
Nevertheless, due to the huge diversity of intestinal microbial exist within different 
individuals, the metabolic profile as well the final impact of certain bioactive compounds 
would also be highly variable. For example, in many situations, only the “products” of 
certain bacterial metabolism can be absorbed and exert the beneficial impact on human 
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health; for people who is lacking of certain microbiota which are necessary for such 
“desirable” biotransformation, the beneficial effect the consumption of the bioactive 
compounds would hardly be achievable [304].	  	  
In conclusion, it will be crucial to elucidate the multiple roles that microbiota plays 
in the development of colorectal cancer as well as the metabolism of certain bioactive 
components. In order to achieve better chemopreventive effect, it will be crucial to make 
dietary suggestion according to the unique “signature” of intestinal microbiota for each 
individual; plus, implantation of new or even genetically altered microbiota while 
excluding carcinogenic species might also be used to maximize the health-promoting 
benefit of the consumption of certain bioactive compounds while minimizing the possible 
tumor-promoting risk such as inflammation.  
5.3 Future Direction  
With the completion of this project, we have gathered important data, which will 
provide rationale for the future pre-clinical and clinical application of PMFs and their 
metabolites in the control of colorectal cancer. Notably, we invested the possible effect of 
PMFs and their metabolites in targeting the CSC subpopulation. The revolutional theory 
of CSC changed our previous view of cancer development. However, the current 
understand of CSCs is still at the infant stage and many issues still haven’ t be solved 
with the complexity of the hierarchical organization of some tumor types. With the 
development of technologies such as gene sequencing, we will be able to gain better 
insights of the stemness nature of CSCs within the tumor bulk. Plus, more attentions 
should also be focused on the interaction between the microenvironment and the CSC 
subpopulation, since it may be playing an important role in maintaining the proper 
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behavior of CSCs. More efforts should be put on the improvement of the purification of 
CSCs, as well as the better understanding of the cross- talk among multiple molecular 
events in the CSC biology.  
The interaction between PMFs and the intestinal microbiota are crucial for 
understanding the role of these compounds and their effects on human health. The 
knowledge obtained in pre-clinical models has to be further verified in human trials. The 
microbiota that would be identified as the key players in the biotransformation of PMFs, 
could thereby be used as biomarkers to anticipate the possible difference responses 
among individuals followed by the consumption of PMFs; while it might also be 
promising that certain PMFs can be chemically modified before consumption to achieve 
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